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Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease which affects   5 - 
8 million individuals worldwide and 200,000 individuals in the United States alone. 
Although prevalent, we do not know what causes IPF and no effective curative 
treatment exists for this disease. Our laboratory has shown that extracellular 
accumulation of adenosine and subsequent activation of the adenosine 2B 
(ADORA2B) receptor promotes immune cell invasion, airspace destruction, and 
fibrosis in chronic lung disease. Additionally, alternatively activated alveolar 
macrophages (AAMs) expressing ADORA2B, have been implicated in mediating 
adenosine’s pro-fibrotic effects in IPF. However, the exact role of AAMs in the hypoxic 
lungs of IPF patients is not known. Our results reveal myeloid-specific ADORA2B 
deletion, antagonism of ADORA2B on AAMs, and inhibition or genetic silencing of 
hypoxia inducible factor 1 (HIF1A) as a means to attenuate pro-fibrotic mediator 
production and pulmonary fibrosis in bone marrow derived macrophages (BMDMs) 
and in vivo models of bleomycin-induced pulmonary fibrosis. These players will be 
valuable as potential clinical targets to halt differentiation of macrophages into the 
reparative AAM subtype and attenuate their subsequent pro-fibrotic role. Ultimately, 
these investigations will lead to a better understanding of adenosine’s role in IPF and 
lead to identification of targets for novel therapeutics that can prevent disease 
progression and possibly reverse lung fibrosis.  
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CHAPTER ONE 
INTRODUCTION 
IDIOPATHIC PULMONARY FIBROSIS 
Definition and Epidemiology 
Idiopathic pulmonary fibrosis (IPF) is a devastating lung disease of unknown 
cause which leads to chronic, progressive interstitial pulmonary fibrosis(1). It is a 
disease which typically affects older males between the ages of 55 and 75(2). IPF is 
believed to affect up to 200,000 alone in the United States and around 8 million 
individuals worldwide (2-4). Nalysnyk et al. estimate the prevalence in the United 
States to be between 42.7-63 cases per 100,000 based on broad case definitions of 
IPF(5). Approximately 14,000 – 34,000 patients receive the new diagnosis of IPF each 
year(3). Ultimately, prevalence and incidence of IPF has been shown to increase with 
age and is continuing to rise emphasizing the need for investigation into the 
pathogenesis of this disease and development of novel therapies to halt its increasing 
incidence (1, 5). 
 
Presentation and Diagnosis 
 Patients with IPF typically present with a chronic, non-productive cough and 
progressive dyspnea, or shortness of breath, on exertion which severely limits their 
quality of life(1, 2, 6). Findings on physical examination will include digital clubbing or 
bibasilar inspiratory crackles(2). Diagnosing IPF requires excluding other known 
causes of interstitial lung disease, the presence of a usual interstitial pneumonia (UIP) 
on high resolution computed tomography (HRCT) in patients without surgical lung 
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biopsy, or findings of possible UIP on HRCT with surgical lung biopsy findings showing 
definite UIP, probable/possible UIP, or non-classifiable fibrosis in conjunction with 
multidisciplinary discussion(1). Findings of definite UIP on histopathology include 
marked fibrosis, including patchy parenchymal involvement, fibroblastic foci, and 
honeycombing in a subpleural or septal distribution in the absence of any features 
suggestive of a different diagnosis (1). Honeycombing refers to clustered cystic 
airspaces with thick, fibrous walls and findings of collapsed alveoli and dilated alveolar 
lumen on pathology (7). HRCT findings suggestive of definite UIP include subpleural 
or basal predominance of reticular abnormalities, honeycombing with or without 
traction bronchiectasis, provided there is no evidence of features inconsistent with UIP 
such as micronodules, cysts, or consolidation(1).  
 
Risk Factors 
Although there is no known cause for IPF, risk factors such as environmental 
exposures, genetic factors, or medical comorbidities may contribute to the 
development of disease(2). A smoking history greater than 20 pack-years has strong 
associations with familial and sporadic IPF(1). Environmental exposures to metal, 
wood, vegetable, or animal dust is associated with significantly increased risk of IPF 
putting those who work in farming, hair dressing, or livestock at risk(1).  
Co-morbid conditions including obesity, obstructive sleep apnea (OSA), 
diabetes, and gastro-esophageal reflux disease (GERD) have been associated with 
IPF(2). 37-94% of patients with IPF are affected by GERD(8). It’s postulated that 
fibrosis changes compliance of the lung, contributing to increased negative 
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intrathoracic pressure and the symptoms of acid reflux; another hypothesis that 
repeated microaspirations contribute to alveolar epithelial cell damage which 
contributes to the repair, remodeling, and abnormal extracellular matrix deposition 
which leads to IPF (1, 8). Diabetes mellitus is found in 10-32.7% of patients with IPF(9) 
however the mechanism by which it may contribute to the pathogenesis of IPF is 
unclear. Some studies have suggested an association with Epstein-Barr virus (EBV) 
and hepatitis C infection in association with IPF however these studies are limited due 
to negative associations in some and significant confounding variables including 
immunosuppressive treatment(1).    
Genetic transmission between families is believed to only affect up to 3.7% of 
patients with IPF (2). ELMOD2, a gene found on chromosome 4q31, in addition to 
mutations in surfactant protein C (spc) and the rare surfactant protein A2 (SFTPA2) 
have been found to be strongly associated with familial cases of IPF, where two or 
more members of the primary biological generation are affected (1). Mutations in 
human telomerase reverse transcriptase (hTERT) and human telomerase RNA (hTR) 
have been found in 15% of familial IPF cases supporting the hypothesis that 
progressive telomere shortening contributes to alveolar epithelial cell apoptosis and 
the initiation of an abnormal wound repair response which leads to the development 
of IPF(1, 2). Sporadic cases of IPF have been associated with genetic polymorphisms 
in genes coding for cytokines (interleukin-1, 4, 8, 10, and 12, and tumor necrosis 
factor alpha (TNF), enzymes (1-antitrypsin, angiotensin converting enzyme), pro-
fibrotic mediators including transforming growth factor 1 (TGF1), and matrix 
metalloproteinase (MMP)-1(1, 10). Recent work by Yang et al. suggest genetic 
polymorphisms in the promoter of mucin 5B (MUC5B) has a strong association with 
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the development of IPF and its increased expression in terminal bronchi suggest 
increased mucous production contributes to perturbed mucociliary clearance and the 
development of pulmonary fibrosis(11).  
 
Natural History of IPF 
A large majority of patients with IPF follow a slow, gradual progression of 
disease while some remain stable, show a rapid decline, or demonstrate repeated 
acute exacerbations (AE)(1). Risk factors that may influence the disease progression 
are not quite understood but emphysema and pulmonary hypertension are believed 
to have a role(1). Patients with a stable or slowly progressive course of disease 
typically do not present to physicians until years (typically >24 months) after the 
symptoms begin although mortality is typically within few years of diagnosis (2, 12). 
Their annual decline in forced vital capacity typically ranges from 0.13 to 0.21L(12).   
Patients are diagnosed with the rapidly progressive IPF subtype when they 
present to their physician within six months of symptoms beginning(12). Although their 
pulmonary function and findings on histology or imaging at the time of diagnosis are 
similar to patients with the slowly progressive subtype, patients with accelerated IPF 
are typically male, smokers, and have been found to have greatly differing 
transcriptional profiles(2). Smoking has been shown to induce inflammation and 
contribute to upregulation of the MAPK-ERG1-HSP70 pathway(13). Microarray data 
from patients with rapidly versus slowly progressive IPF found 437 differentially 
expressed genes including overexpression of genes related to morphogenesis, 
oxidative stress, migration and proliferation of fibroblasts and smooth muscle 
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cells(14). Immunohistochemistry of lung sections from rapid progressors also showed 
increased staining of ADORA2B in alveolar epithelial cells(14).  
Five to ten percent of patients will experience repeated acute exacerbations 
(AE) or periods of respiratory decline within days to weeks(1).  Acute exacerbations 
may be secondary to infection or cardiac failure(1). If in the absence of a known cause 
but associated with worsening symptoms of one month, lung function, bilateral 
ground-glass opacities and reticular consolidation on HRCT, is then referred to as 
acute exacerbations of IPF(1, 12). Mortality amongst these patients exceeds 60% 
during hospital admissions and increases to 90% within 6 months after discharge(2). 
Although there are no established risk factors for AE of IPF, it has been associated 
with post-operative thoracic surgery, bronchoalveolar lavage fluid (BAL) collection, 
and Torque teno virus in 27% of affected patients(2, 12). It is unclear however if AE 
of IPF represent a separate disease process from IPF or results from acute pulmonary 
distress leading to exacerbations of fibrotic changes in IPF(15). Examination of BAL 
typically reveals neutrophilia and histology shows diffuse alveolar damage (DAD) 
indicative of alveolar epithelial cell injury and remodeling as a mechanism of injury in 
AEs of IPF(15).  
 
Treatment  
 In the past, as IPF was believed to largely be a disease secondary to 
aggressive inflammation alone, treatment had been primarily limited to corticosteroid 
treatment with no significant clinical improvement, little survival benefits and significant 
long-term comorbidities(1, 15).  
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 Pharmacologic therapies which have failed placebo-controlled trials include 
Etanercept, a recombinant soluble human TNF receptor which binds and neutralizes 
TNF, an inflammatory cytokine found to be elevated in patients with IPF(15). 
Bosentan, an endothelin-1 (ET-1) receptor antagonist, was predicted to inhibit ET-1-
mediated collagen production, and matrix turnover; however, the BUILD-1 study 
showed no significant difference over placebo in 6 minute walking distance (6MWD) 
among treated patients(15). Similarly, macitentan, a nonselective ET receptor 
antagonist, was shown to have little effect on forced vital capacity against placebo in 
a phase 2 trial(16).  The phase 3, randomized, double-blind, placebo-controlled 
anticoagulant effectiveness in idiopathic pulmonary fibrosis (ACE-IPF) trial was 
suspended due to ineffectiveness of warfarin treatment in patients with IPF over 
placebo(2).  
 Sildenafil, a phosphodiesterase 5 inhibitor, decreases pulmonary vascular 
constriction, reduces resistance, and has been shown to improve gas exchange and 
dyspnea in patients with severe IPF although no differences in 6MWD, the primary 
outcome was observed (2, 17).  
 The PANTHER-IPF study evaluated the change in baseline FVC after 60 
weeks among patients with mild to moderate IPF who received either treatment with 
placebo, N-acetylcysteine (NAC) monotherapy, or prednisone and azathioprine and 
NAC therapy(18). No significant difference was observed in the rate of FVC decline or 
frequency of AEs(18). There were frequent hospital admissions and eight deaths in 
the three-drug group which prompted the Data and Safety Monitoring Board to stop 
the study and discontinue the use of the triple-drug therapy(18).  
23 
 
Pirfenidone is believed to inhibit fibroblast proliferation and collagen production 
through its inhibition of TGF and TNFInitial Phase II trials showed no difference in 
pirfenidone treatment as compared to placebo with respect to changes in arterial 
oxygen saturation after 6MWD however vital capacity (VC) was significantly 
improved(19). A phase III randomized control trial in Japan revealed significant 
differences in VC decline between placebo and high or low dose treatment groups 
leading to its approval in 2008 for the treatment of IPF(20). The multinational phase II 
CAPACITY 1 trial showed significant difference in % FVC change from baseline after 
72 weeks in patients with pirfenidone treatment as compared to placebo leading to its 
approval in European countries in 2011 for IPF treatment(21). It was not until the 
phase III ASCEND trial which demonstrated improvements in FVC, 6MWD, 
progression free survival, and a reduction in death at 1 year by 48% that the FDA 
approved pirfenidone for treatment of IPF patients in the United States in October 
2014(22). Mild to moderate side effects include gastrointestinal, dermatologic, 
neurological symptoms, and elevated liver enzymes(23).  
Nintedanib inhibits vascular endothelial growth factor (VEGF), platelet-derived 
growth factor (PDGF), and fibroblast growth factor (FGF) receptors halting the 
progression of fibrosis, slowing the decline in FVC, and AEs in patients receiving 
treatment compared to placebo. Phase III trials showed twice daily administration of 
nintedanib for 52 weeks led to slowing of the rate of FVC decline although there was 
no difference with respect to time to AE. Given these results however, Nintedanib was 
approved by the FDA for treatment of patients with IPF in October 2014 as well(24). 
Diarrhea was a significant adverse effect which impacted 90% of patients(23). 
However, a recent network meta-analysis comparing Pirfenidone and Nintedanib 
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show no significant difference in either drug’s ability to lower respiratory-specific or all-
cause mortality or decline in percent FVC (22, 24, 25). 
Lung transplant remains the only ‘curative’ treatment that can increase survival, 
and even then, it only mildly improves 5 year survival rates to 50-56%(1). Other 
supportive and preventative treatment approaches include pulmonary rehabilitation, 
smoking cessation, immunization against influenza and pneumococcus, control of 
GERD, and oxygen therapy to keep saturations above 90%(15). There is some recent 
evidence however which suggests that oxygen therapy may not have any additional 
benefit over air in reducing exertional dyspnea among IPF patients without hypoxemia 
at rest(6). 
Recent compounds in Phase 2 clinical trials include Fresolimumab, which targets 
TGF, FG-3019, a monoclonal antibody against connective tissue growth factor, 
Rituximab which targets Anti-CD20, and Sirolimus which inhibits mTOR(23). Several 
compounds have been developed against IL-13 including Lebrikizumab, OAX-576, 
Tralokinumab, and SAR156597 which actually targets IL-13 and IL-4(23).   
 
Prognosis 
 Median survival for patients with IPF is between 2-3 years secondary to 
ineffective therapies (2, 26). There were approximately 175, 000 deaths due to 
pulmonary fibrosis from 1992 to 2003 which is about 51 deaths per 1,000,000 people 
when adjusted by age and sex. In fact, mortality during that time period increased by 
28.4% in men and 41.3% in women(27). Five year survival rate among patients with 
IPF is only 43%(28). Poor prognostic factors include age greater than 70 years old, 
smoking history greater than 20 pack-year, and low body mass index (2). Other factors 
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of poor prognosis at baseline include diffusion limited capacity less than 40% of 
predicted, desaturations in arterial oxygen saturation to less than 88% during 6MWT, 
reductions in FVC by more than 10%, extensive honeycombing on HRCT, and 
pulmonary hypertension(1, 23). 9.8-38% of IPF patients may go on to develop 
malignancies including bronchogenic carcinoma(2).  
 
Pathogenesis of IPF 
Despite its significant prevalence, little is known about the mechanisms that 
lead to the development and progression of IPF and contributes to its poor prognosis 
(15). The failure of anti-inflammatory therapies for IPF including corticosteroids has 
largely refuted the hypothesis that IPF is primarily an inflammatory condition (2, 15). 
Epithelial cell injury and activation by genetic and environmental factors discussed 
above including smoke exposure, chronic microaspirations, or infection are instead 
believed to be the main pathway contributing to the development of fibrosis(15). 
Alveolar epithelial cells have been shown to secrete mediators which promote 
recruitment, proliferation, and differentiation of mesenchymal cells, fibrocyte 
infiltration; in fact, transitions of epithelial cells to mesenchymal cells (termed EMT or 
epithelial to mesenchymal transition) is believed to account for 33% of fibroblasts in 
mouse models of lung fibrosis(2). Hung et al. have also demonstrated the presence 
of pericytes, or cells derived from Foxd1-expressing progenitors, which expand after 
bleomycin-induced injury to myofibroblasts and fibroblasts and contribute to the 
deposition of extracellular matrix and fibrosis(29).  
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Proteins critical to embryogenesis have also been found to be abnormal in IPF. 
Wnt ligands have found to be overexpressed in alveolar epithelium and fibroblasts 
from IPF patients in addition to downregulation of phosphatase and tensin homologue 
(PTEN) in myofibroblasts, contributing to their resistance to apoptosis(2). 
Myofibroblasts are essentially ‘activated’ fibroblasts with greater contractility and pro-
fibrotic potential(2). Increased gremlin expression, a bone morphogenetic protein 
antagonist, has also been observed in IPF fibroblasts (2).  Moreover, much remains 
to be understood regarding the pathogenesis of lung tissue injury, remodeling, and 
fibrosis development emphasizing the significance of work presented in this 
dissertation.  
 
ACUTE LUNG INJURY 
Definition and Epidemiology 
 Acute lung injury (ALI) is a devastating lung disease of acute onset which often 
progresses into acute respiratory distress syndrome (ARDS), respiratory failure, and 
death(30). It is characterized by pulmonary edema due to breakdown and increased 
permeability of the alveolar capillary barrier which contributes to impaired arterial 
oxygen saturation in affected patients (31). It is estimated that the incidence in the 
United States is 190,600 individuals per year(30, 32). Although incidence of hospital-
acquired ARDS is declining since changes in standard of practice with respect to lung-
protective mechanical ventilation, the incidence of community-acquired ARDS 
remains the same(32). Moreover, there still remains a large clinical need to identify 
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mechanisms behind the development of inflammation, pulmonary edema, and 
hypoxemia in order to develop targeted therapeutics that can reduce its incidence.  
 
Presentation and Diagnosis 
 Patient typically present with tachypnea, or increased respiratory rate, and 
hypoxemia(30). Criteria for diagnosis of ALI include acute onset within 1 week of a 
known insult or worsening symptoms, the presence of diffuse pulmonary infiltrates, 
PaO2/FiO2 ≤ 300, and the absence of symptoms that suggest cardiac failure (31, 32). 
Early phases of disease show bilateral, ground-glass opacities which develop 
secondary to interstitial edema and hyaline membrane deposition(30).  
Epithelial and endothelial barrier dysfunction contribute to diffuse alveolar 
damage (DAD) which can be classified into three phases on histology. In the acute or 
exudative phase, hyaline membranes are observed lining the alveolar space in 
addition to edema with contributing to the eventual development of granulation tissue; 
alveolar hemorrhage may be present and type II epithelial cells become 
hyperplastic(30). In the proliferative phase, granulation tissue incorporates into the 
alveolar septa leading to squamous metaplasia(30). Finally, the fibrotic phase is 
characterized by collagen deposition and alveolar hyalinization(30).    
 
Risk Factors 
 Generally, risk factors for ALI can be divided into predisposing medical 
conditions, including shock, sepsis, aspiration, pneumonia, and surgery, or risk 
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modifiers such as obesity, alcohol abuse, tachypnea, and oxygen 
supplementation(32). However, infection including pneumonia or sepsis are the 
greatest factors shown to lead to ALI development at 46% and 33%, respectively(32). 
Additionally triggers which directly affect the lung including microaspiration, 
ingestants, inhalants, hyperoxia, ventilator induced injury, and bleomycin can lead to 
the development of ALI (30, 31). Systemic inflammatory response syndrome (SIRS) 
in response to pancreatitis or transfusions can also contribute to ALI(31). Patients with 
other medical comorbidities including chronic lung disease or alcohol abuse are also 
found to have increased incidence of ALI(32). Interestingly, both Type 1 and Type 2 
diabetes mellitus has been found to have a protective effect in septic and nonseptic 
patients with ALI(32).  
 
Treatment  
 Treatment is primarily aimed at addressing the underlying cause in addition to 
supportive care which may include mechanical ventilation and corticosteroid therapy. 
Phase 3 trials demonstrated significant reductions in mortality and greater ventilator-
free days when low tidal volumes are used (6cc/kg of predicted body weight)(33). 
Implementation of changes in mechanical ventilation based on these trials has 
contributed to the reduced incidence by almost 40% of ALI developing into hospital-
acquired ARDS(32).  
 The Lung Injury Prevention study with Aspirin (LIPS-A) is a recent phase 2 trial 
which evaluated the impact of prophylactic aspirin administration versus placebo on 
reducing ALI incidence in patients already on invasive mechanical ventilation; 
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however no reductions in ARDS incidence was observed so a phase 3 trial was not 
initiated(34). The recent phase 2 clinical trial evaluating aerosolized budesonide, an 
inhaled corticosteroid, and formoterol, a beta-agonist, treatment against placebo 
shows promise however in that combined treatment demonstrated improvements in 
oxygenation, PaO2/FiO2 ratio, decreased incidence of ARDS, and reductions in 
hospital stay(35).  
 
Prognosis 
 Typically, patients with ALI will develop ARDS within 2-5 days of 
hospitalization(30). Factors which influence mortality include ALI severity whether it 
be mild (200 < PaO2/FiO2 ≤ 300), moderate (100 < PaO2/FiO2 ≤ 200), or severe 
(PaO2/FiO2 ≤ 100) associated with increasing mortality rates of 27%, 32%, or 45% 
respectively(32). Males and African Americans affected by ALI also exhibit increased 
mortality however rates generally declines as time from admission increases(30, 32). 
Since 2010, the rate of in-hospital mortality is approximately 45%, ICU-associated, 
38%, 30d after discharge, 30%, and 32% at 60 days from discharge(36). Overall 
however, there has been no significant improvement in mortality over the past two 
decades (30, 31).  
 
Pathogenesis of ALI  
There is extensive evidence suggesting the role of inflammation in ALI. After 
the initial insult, neutrophils are often the first cell type to infiltrate the lung releasing 
chemokines that attract macrophages and other mononuclear cells(37). Activated 
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neutrophils release proteases, reactive oxygen species (ROS), and peptides that 
contribute to the apoptotic and necrotic cell death of endothelium and epithelium(37). 
This breakdown of the pulmonary barrier contributes to increased permeability, 
pulmonary edema, and further inflammation (37, 38). Therapeutic inhibition of 
neutrophil-dependent CXCR2 (the chemokine receptor for IL-8, a known neutrophil 
chemoattractant) in a bleomycin-induced model of ALI was shown to be protective in 
addition to bleomycin exposure in IL-1-/- and IL-18-/- mice(31). These studies highlight 
the importance of neutrophil migration and activation in contributing to acute lung 
injury. Recruited anti-inflammatory macrophages also play a key role in resolving 
inflammation. Janssen et al demonstrated the importance of Fas-mediated apoptosis 
in bone-marrow recruited macrophages (CD11bhigh) in resolving inflammation in a 
H1N1-model of acute lung injury while populations of resident macrophages 
(CD11chigh) were stable (39).  
Chemokines including macrophage inflammatory protein-1alpha (MIP-1), a 
monocyte and leukocyte chemoattractant contributes to acute inflammation in acute 
lung injury models through TNF and IL-6 release (38). Monocyte chemotactic 
protein-1 (MCP-1) is a chemokine produced by mononuclear cells including lung 
macrophages and contributes to increased inflammation in the development of lung 
injury(38). BALF levels of chemokines including CXCL1 and CXCL8 are elevated in 
patients with ALI(40). As such, some investigators have focused on antibody blockade 
of chemokines and or their receptors to attenuate ALI in animal models of disease 
however these findings have yet to be translated to trials in humans with ALI/ARDS.  
 Pathogen associated molecular patterns (PAMPs) and damage-associated 
molecular patterns (DAMPs) typically serve to initiate responses by the innate immune 
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system including TNF, IL1, and IL-8 release(30). One key DAMP includes 
hyaluronan, an extracellular matrix glycosaminoglycan, produced in the setting of lung 
injury binds Toll-like receptors (TLR) 4 and 2 inducing inflammation(30). In fact, 
overexpression of high-molecular weight hyaluronan has been shown to be protective 
against lung injury in animal models by NF-kappaB activation protecting from further 
epithelial cell apoptosis(41).  
 Biomarkers to date which have been found to be elevated in plasma and BAL 
amongst patients with ALI include TNF, IL-1, IL-6, IL-8, and IL-18(30). IL-8 is 
interesting of note due to its ability to activate and attract neutrophils by binding with 
anti-IL-8 autoantibodies which inhibit neutrophil apoptosis(42, 43). Neutrophils are 
one of the first cells to respond and infiltrate the lung after ALI(31). Additionally, 
concentration of these IL-8-anti-IL-8 autoantibodies along with IL-18 levels is a direct 
indicator of ALI disease severity and mortality (44, 45). Despite the advances in 
understanding the pathophysiology which lead to the development of acute lung injury, 
there are few molecular-based therapies which have been shown to reduce mortality 
and improve quality of life for the patients who survive ALI and ARDS; as such, 
findings presented in this thesis on the impact of hypoxia and HIF1A stabilization are 
valuable to driving development of novel treatments for ALI.  
 
ADENOSINE SIGNALING IN LUNG DISEASE 
Adenosine Metabolism and Signaling  
Adenosine is a potent signaling molecule that exerts its effects by acting on 
four G-protein coupled receptors (GPCRs), ADORA1, ADORA2A, ADORA2B, AND 
32 
 
ADORA3(46, 47). These receptors lead to changes in intracellular cAMP and calcium 
which ultimately, regulate homeostatic functions within the cell(48). ADORA1 and 
ADORA3 are Gi coupled so activation leads to reduced cAMP levels while ADORA2A 
and ADORA2B are Gs coupled stimulating adenyl cyclase, increasing cAMP and 
protein kinase A activation(48). ADORA2B can also couple to Gq stimulating 
phospholipase C (PLC) contributing to calcium release and protein kinase C (PKC) 
activation(48). Generally, the ADORA1 and ADORA2A receptor have higher affinity 
for adenosine than the low-adenosine affinity ADORA2B and ADORA3A 
receptors(49). Physiologic levels of adenosine in the extracellular fluid range from 40-
600nM and its accumulation in the extracellular space is secondary to passive transfer 
from the intracellular space (50). Two bi-directional carriers responsible for passive 
diffusion of adenosine are equilibrative nucleoside transporter (ENT)-1 and ENT-
2(49). Adenosine can be deaminated to inosine by adenosine deaminase (ADA) or 
phosphorylated by adenosine kinase to ATP(49).  
In settings of cellular injury induced by hypoxia, trauma, or chronic 
inflammation, ATP is released from affected cells and subsequently dephosphorylated 
by the membrane bound enzyme ectonucleoside triphosphate diphosphohydrolase 
CD39 to AMP followed by dephosphorylation to adenosine by ecto-5’-nucleotidase 
CD73 to produce elevations in adenosine in the extracellular space(51, 52). 
Adenosine concentrations have been found to be as elevated as 100M in asthma 
and COPD(50). Activation of the different adenosine receptors have been found to 
have differing effects depending on the injury model and cell-type. For example, 
antagonism of ADORA1 and ADORA3 have been associated with reduced 
inflammation in models of cecal ligation (50). ADORA2A has been shown to maintain 
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integrity in cardiac and renal models of ischemic reperfusion injury while ADORA2A 
provides systemic organ protection (50).  
 
Adenosine Signaling in Chronic Lung Disease 
Previous work suggests that pulmonary fibrosis results from an abnormal tissue 
reparative response(53). We have demonstrated how the nucleoside adenosine plays 
a critical role in the regulation of this response in the lung and contributes to 
fibrosis(50, 54-56). Adenosine levels are elevated in chronic lung diseases including 
asthma, COPD, and IPF(55, 57, 58). Mouse models of lung injury show increased 
adenosine levels in bronchoalveolar lavage fluid associated with increased 
inflammation and fibrosis(56).  
These elevations in adenosine have been found to have differing tissue protective 
versus tissue destructive effects depending on the adenosine receptor activated and 
cell type. One mouse model that has been used to understand the effects of 
adenosine-mediated lung injury is the Adenosine Deaminase (ADA) deficient model 
(ADA-/-) in which adenosine accumulates in the extracellular space due to the lack of 
the ADA enzyme which catalyzes its breakdown(59). ADA-/- mice exhibit abnormalities 
in alveologenesis, airway enlargement and obstruction, along with pulmonary 
inflammation, that contributes to the development of pulmonary fibrosis which is 
attenuated with introduction of ADA enzyme supplementation (60, 61). This model has 
ultimately allowed evaluation of adenosine-mediated lung injury. Adenosine 
stimulation itself promotes release of IL-8, IL-4, and IL-13 from mast cells. Overall, 
ADORA1 and ADORA2A have been found to have a tissue-protective role in 
34 
 
adenosine-mediated lung injury as ADA-/-/ADORA1-/- and ADA-/-/ADORA2A-/- mice 
showed exacerbations in inflammation and mucous cell metaplasia(62, 63). 
Meanwhile, activation of ADORA2B and ADORA3 are associated with tissue-
destructive effects enhancing inflammation and fibrosis, or mast cell degranulation 
and mucous metaplasia, respectively (50).  
The ADORA2B receptor is unique in several ways including its low affinity for 
adenosine and promotion of anti-inflammatory and anti-fibrotic features in acute lung 
injury(54). However, our lab has previously shown that chronic extracellular adenosine 
accumulation and activation of ADORA2B receptor can lead to features of chronic 
lung disease including inflammation, fibrosis, and tissue remodeling (56).  Evaluating 
lung sections from IPF patients who are rapid progressors has also shown increased 
immunohistochemical staining for ADORA2B in association with increases in matrix 
metalloproteinases (MMPs) in IPF BALF promoting increased fibroblast migration in 
comparison with slow progressors (14).  
ADORA2B is found throughout many cell types in the lung including epithelial 
cells, macrophages, fibroblasts, and smooth muscle cells (64). However, ADORA2B-
mediated release of the pro-inflammatory and pro-fibrotic cytokine, IL-6, from 
macrophages has proven to be of unique interest. IL-6 itself is known to target 
inflammatory mediators including CXCL1, MCP-1, osteopontin (OPN), and IL-17 (65). 
CXCL1 itself, the murine analog of human neutrophil chemoattractant, IL-8, was found 
to be elevated in lungs of ADA-/- mice and neutralization of CXCL1 and its receptor, 
CXCR2, was found to inhibit adenosine-mediated angiogenic activity in the lung(66).  
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Zhou et al. demonstrated ADORA2B expression on CD206 positive macrophages 
in macrophages from BALF of IPF patients and revealed a role for ADORA2B 
antagonism in decreasing IL-6 production from macrophages isolated from IPF 
patients (55). Supporting a role for ADORA2B in mediating IL-6 production, 
ADORA2B-/- mice were observed to have reduced IL-6 expression in BALF on day 33 
after bleomycin exposure in association with reductions in IL-6 immunohistochemical 
staining localized to lung macrophages(56). Lung macrophages isolated from ADA-/- 
mice, known to have exacerbated inflammation, alveolar destruction and fibrosis 
secondary to adenosine elevations, showed elevations in IL-6 transcripts which were 
further increased with treatment by the adenosine receptor agonist, NECA, and 
reversed upon addition of ADORA2B-specific antagonist, MRS 1754 (65).  
 
Adenosine Signaling in Acute Lung Injury 
 As discussed above, ALI is characterized by initial influx of neutrophils into the 
lungs and a Th1 cytokine rich environment including increases in IL-12, IFN, and 
TNF(50). Models of LPS-induced ALI have demonstrated exacerbations neutrophilia 
and pulmonary barrier dysfunction in CD39 and CD73 deficient mice associated with 
reductions in adenosine thereby suggesting adenosine itself plays an anti-
inflammatory role in ALI(67). ADORA2A and ADORA3 agonists have also been 
utilized in transplantation lung reperfusion injury models and cardiopulmonary bypass-
induced lung injury models to attenuate inflammation and preserve pulmonary 
function(50). ADORA2B antagonist treatment in a ventilator-induced lung injury model 
demonstrated increases in pulmonary inflammation, edema, decreased gas 
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exchange, and reductions in survival time (68). Similarly, we have previously 
demonstrated a tissue-protective role for ADORA2B as exacerbations in pulmonary 
edema, inflammation, and barrier dysfunction were observed in ADORA2B-/- mice 
exposed to bleomycin intratracheally(56).  Bleomycin treatment of ADORA3-/- mice 
also showed enhanced inflammation and eosinophilia suggesting ADORA3 also 
serves an anti-inflammatory role in ALI (69).  
 Evidence in animal models of acute and chronic lung disease and patient 
samples reveal that adenosine receptors have differing anti-inflammatory, tissue-
protective or pro-inflammatory, tissue-destructive roles depending on the stage of 
disease or cell-type involved(50, 52). Although it is not clearly understood what 
contributes to these differences depending on disease stage, it may likely be a feature 
of differences in the cytokine environment with acute injury being primarily Th1 and 
chronic stages of disease, Th2 (50). This dissertation will focus on the role of 
ADORA2B on myeloid cells in acute lung injury and chronic lung disease in a 
bleomycin-induced model of lung injury along with how hypoxia can regulate these 
responses.  
 
HYPOXIA-INDUCIBLE FACTOR 1A (HIF1A) IN LUNG DISEASE 
Hypoxia inducible factor-1A (HIF1A) Signaling 
Hypoxia inducible factor (HIF) is a transcription factor responsible for regulating a 
variety of target genes including those involved in angiogenesis, matrix metabolism, 
apoptosis, and glycolysis(70, 71). It is composed of two subunits: the inducible alpha 
(HIF1A) and constitutively expressed beta unit (HIF1B)(70). In normoxic conditions, 
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von hippel Lindau (VHL) protein targets the HIF1A subunit for proteasomal-mediated 
degradation followed by prolyl hydroxylation of the oxygen dependent domain (ODD) 
by three prolyl hydroxylases (PHD 1,2 and 3)(70). Another player which can disrupt 
HIF transcription is Factor inhibiting HIF1, or FIH. FIH hydroxylates asparagine 
residues within HIF1A or HIF2A, preventing the interaction of HIF with its 
transcriptional co-activator p300.(70).  
In settings of hypoxia, PHD enzyme activity decreases resulting in decreased 
hydroxylation of HIF1A promoting its stabilization and accumulation in the 
cytoplasm(72). Next, it translocates to the nucleus where it binds to the constitutively 
expressed HIF1B and the heterodimer bind to hypoxia response elements (HRE) on 
the promoter region of target genes, recruits coactivator proteins, and initiates 
transcription of the target gene (71).  
HIF1A can also be stabilized in normoxic conditions such as bacterial 
lipopolysaccharide (LPS) treatment, iron uptake by bacteria during infection, or 
mechanical stretch which increases ROS inhibiting PHDs(73, 74). NF-kb activation of 
the innate immune system, PI3K/Akt pathway activation in response to insulin-like 
growth factor (I-LGF) can also stabilize HIF1A in the absence of hypoxia(74, 75). 
Elevations in succinate have also been shown to directly inhibit PHD activity in 
macrophages leading to stabilization of HIF1A(76, 77). Additionally, increased 
succinate production can contribute to increased ROS production which can oxidize 
PHD cofactors ultimately resulting in the stabilization of HIF1A(77, 78).  
Agents or means which have been demonstrated to stabilize HIF1A include siRNA 
against FIH and CoCl2, which acts as PHD inhibitor(70, 79). Pharmacologic inhibitors 
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of HIF1A include 17-DMAG, an inhibitor of heat shock protein 90 (hsp90), leading to 
improper folding of HIF1A, its destabilization and subsequent degradation(80).  
 
HIF1A in Chronic Lung Disease 
On history, physical and laboratory examination, IPF patients often 
demonstrate features of chronic hypoxia including shortness of breath, reduced 
diffusion capacity of the lung and 6 minute walk distance, and decreased partial 
pressure of oxygen in arterial blood(2, 81). Increased immunohistochemical staining 
for HIF1A on histological evaluation of lungs from IPF patients also supports the 
presence of hypoxia(82). Similarly, animal models of bleomycin-induced chronic 
pulmonary fibrosis show decreased arterial oxygen saturation and increased HIF1A 
in the lungs(83). Weng et al. demonstrated in vitro and in vivo how hypoxia-induced 
stabilization of HIF1A contributes to induction of deoxycytidine kinase (DCK) and 
subsequent alveolar epithelial cell proliferation contributing to the development of 
severe lung fibrosis(84). In vivo inhibition of HIF1A in a house dust mine (HDM) model 
of chronic asthma led to decreases in eosinophilia, inflammation, reductions in VEGF 
and CXCL1 in association with fewer endothelial progenitor cells and peribronchial 
angiogenesis(85). Together these studies illustrate HIF1A contributes to inflammation 
and fibrosis in chronic lung disease.  
 
HIF1A in ALI 
 A role for HIF1A in acute lung injury is only recently being elucidated and is still 
unclear depending on the model of lung injury and cell-type involved. HIF1A up-
regulation in a hypoxia/ischemia reperfusion model led to an increase in VEGF and 
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disruptions of the vascular barrier suggesting a tissue-destructive role for HIF1A in 
acute injury(72). Similarly, stabilization of HIF1A in neutrophils was revealed to 
promote NF- activation, preventing their apoptosis after in vitro hypoxia exposure 
suggesting a pro-inflammatory role for HIF1A(86). However, HIF1A-dependent 
reduction in adenosine kinase led to an increase in adenosine levels that protected 
the vascular barrier(72, 87). Also demonstrating an anti-inflammatory role for HIF1A 
in acute injury, a normoxic model of ventilator-induced lung injury (VILI) by mechanical 
stretch led to HIF1A stabilization which was associated with reductions in pulmonary 
edema and inflammation(88). Alveolar-epithelial cell specific HIF1A deletion however 
led to exacerbations of acute lung injury in association with suboptimal carbohydrate 
metabolism after VILI emphasizing an anti-inflammatory role for HIF1A in alveolar 
epithelial cells(89).  
 
HIF1A and Adenosine Signaling 
 HIF1A is known to regulate elements of the adenosine pathway. Specifically, 
HIF1A has been shown to regulate expression of the ADORA2B receptor, by binding 
to the HRE of its promoter, CD73, and equilibrative nucleotide transporters (ENTs) 
which allow adenosine transport across the cell membrane (88, 90, 91). This 
regulation ultimately leads to elevation of extracellular adenosine levels and 
enhancement of ADORA2B signaling.  
The promoter of CD73 has also been found to have a HIF1 binding site and in 
vivo studies of a mouse model of hypoxia-induced intestinal injury showed CD73 
inhibition increased barrier disruption, supporting a protective role for CD73 in 
hypoxia-mediated acute injury(92). Cyclic mechanical stretch of pulmonary epithelia 
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and in vivo model of VILI has been shown to promote HIF1A stabilization and 
significant increases in ADORA2B which were reduced with HIF1A inhibition in vitro 
and epithelial-cell specific HIF1A deletion (88). These studies suggest a role for HIF1A 
in modulating players in the adenosine signaling pathway that contribute to tissue 
protection in acute lung injury.  
Most recently, we demonstrated up-regulation of HIF1A along with ADORA2B, 
CD73, and ENT-1 in tissue samples from patients with Group 3 pulmonary 
hypertension (PH), or PH associated with chronic lung disease, in association with 
increased succinate levels, a known HIF1A stabilizer as discussed above(93). As 
HIF1A has been shown to regulate ADORA2B expression and ADORA2B has been 
found to be elevated and localized to alternatively-activated macrophages in IPF 
patients, this dissertation will further investigate the role HIF1A plays on modulating 
ADORA2B expression on myeloid cells and macrophage differentiation.  
 
ALTERNATIVELY-ACTIVATED MACROPHAGES (AAMs) 
Macrophage Subtypes 
Monocytes circulate in the vasculature prior to entering tissues where they 
become macrophages, either long-living tissue-specific as residents, or are recruited 
to phagocytose and kill infectious agents, scavenge toxins, or act as antigen 
presenting cells(94, 95). Therefore, mononuclear cells play a key role in the 
inflammatory response and wound repair response in a variety of tissues (48, 94-96).  
Macrophages can generally be classified into two larger subtypes: classically 
activated and alternatively-activated. Classically-activated macrophages (CAMs) are 
activated by Th1 cytokines including TNF, IFN, granulocyte macrophage-colony 
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stimulating factor (GM-CSF), PAMPs (i.e. LPS), or DAMPs(48, 74, 96). CAMs produce 
inducible nitric oxide synthase (iNOS), TNF, IL-1, and IL-12(96). Their primary 
function is pro-inflammatory to contain microbes and tumoricidal and anaerobic 
glycolysis predominantes (74, 96).  
Alternatively-activated macrophages (AAMs) are polarized by activation with 
Th2 cytokines including IL-4 (binds IL-4R activating Signal transduction and activator 
of transcription (STAT)6), IL-13 (shares STAT6 signaling), IL-6, IL-10 (activates 
STAT3), M-CSF, and MCP-1(74, 96-98). A novel pharmacologic inhibitor of STAT6 
signaling is AS1517499 which disrupts IL-4 and IL-13-mediated differentiation of macs 
into AAMs(97, 99-101). Mauer et al have demonstrated in a diet-induced obesity 
mouse model that IL-6 expression induced IL-4R on macrophages, increasing their 
responsiveness to IL-4 and subsequent AAM activation(102). 
AAMs predominantly express Arginase-1 and mannose receptor C, or CD206, 
along with found in inflammatory zone-1 (FIZZ-1), and chitinase3-like-3 (Ym1). 
Arginase-1 is an enzyme which metabolizes arginine to urea and ornithine, which is 
subsequently utilized for proline and collagen synthesis thereby contributing to 
extracellular matrix (ECM) deposition(48, 96). In fact, Arginase-1 competes with iNOS, 
produced by CAMs, for the arginine substrate thereby reducing nitric oxide production 
(96). AAMs also utilize oxidative glycolysis and fatty acid oxidation as opposed to 
anaerobic pathways(74). CD206 is also a key glycoprotein important to AAM 
phagocytosis function by increasing efferocytosis of pathogens and apoptotic 
cells(103).  
Ultimately, AAMs regulate wound healing through release of matrix degrading 
enzymes and growth factors, and lead to fibrosis by stimulating myofibroblast 
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activation, proliferation, and survival(94, 95, 98). Flow cytometry analysis of lung 
macrophages after a bleomycin-model of lung injury reveal during initial stages or at 
rest, markers which predominate are CD11c+CD11b- indicative of resident 
macrophages however in later stages of injury after fibrosis development, a majority 
of macrophages are recruited macrophages, or CD11c+CD11b+(104). Additional 
functions of AAMs including protection from parasites and suppression of the Th1 
response(74). TNF treatment of bleomycin exposed mice led to reductions in fibrosis 
and AAM expression supporting a role for AAMs in the development of lung fibrosis 
and the potential of encouraging macrophage switch to CAMs as a possible 
treatment(105). AAMs have been found to be a regulatory effector cell type involved 
in remodeling in many diseases including asthma, COPD, CF, and liver fibrosis(95). 
 
Adenosine and Macrophages 
There is evidence that the key effector cell type influenced by ADORA2B 
receptor signaling in pulmonary fibrosis is the lung macrophage. Lung macrophages 
increase over time in animal models of fibrosis(106). Previous work by our lab has 
shown that IPF patients have increased ADORA2B receptor positive alternatively 
activated macrophages (AAM) and we have also shown that the presence of the 
ADORA2B receptor on these macrophages is critical to the production of pro-fibrotic 
cytokines such as interleukin-6 (IL-6)(55, 56). In support of a pro-fibrotic and AAM 
promoting role for ADORA2B in another chronic lung disease, global and myeloid-
specifc ADORA2B deletion in a cockroach allergen mouse model of asthma led to 
reductions in inflammatory cell infiltration, airway mucin production, and decreased 
secretion of pro-inflamamtory cytokines including TNF, tm, and IL-17(107). Th2 
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cytokines IL-4, IL-5, and IL-13 were also reduced demonstrating ADORA2B on 
myeloid cells as a regulator of a Th2 rich environment in the development of chronic 
inflammation in asthma (107). Additionally, Csoka et al have indicated a role for the 
ADORA2B receptor, and to a lesser extent, ADORA2A, in mediating differentiation of 
macrophages into the AAM phenotype (108).  
Like ADORA2B, the other adenosine receptors have also been found to affect 
macrophage differentiation and function. Adenosine itself has been shown to stimulate 
IL-10-induced STAT3 signaling and subsequent activation of M2c macrophages(109). 
Activation of ADORA1 on monocytes leads to differentiation of multinucleated giant 
cells(48). Both ADORA2A and ADORA2B have been found to be pivotal to 
macrophage metabolism as they can increase Specificity protein (Sp1) expression 
promoting increase in glycolytic flux, a metabolic shift believed to play a role in shifting 
CAMs to AAMs(48). Moreover, there is significant evidence that ADORA2B drives 
differentiation of AAM, however this dissertation seeks to delineate the disease signals 
which drive this response whether it be Th2-cytokine-STAT6 mediated or hypoxia 
through HIF1A.  
 
HIF1A and Macrophages  
 Hypoxia in the setting of inflammation has been observed to cause significant 
changes in functional plasticity of macrophages, which account for 95% of the 
recruited cells(74). Changes observed in gene expression include up-regulation of 
VEGF, MMP7, MMP9, and M2 markers such as Arginase-1(96, 110). Cramer et al 
demonstrate that HIF1A deletion on myeloid cells leads to depletion of the ATP pool 
which is associated with poor myeloid cell invasion, motility, and bactericidal abilities 
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suggesting that HIF1A can directly impact macrophage metabolism and subsequent 
survival and function in the setting of inflammation(110). HIF1A-/- macrophages have 
reductions in bactericidal activity, angiogenesis, worsened systemic infection, and 
reduced TNF and IL-6 responses(111).  Hypoxia through HIF1A in T lymphocytes 
has been shown to promote the shift of cells from T helper 1 (Th1) to T helper 2 (Th2); 
this shift in the T helper cell environment can directly influence cytokines released into 
the extracellular environment and mediate macrophage differentiation as discussed 
above(112). Limited studies so far suggest that HIF1A in myeloid cells affects 
macrophage metabolism, function, and gene expression suggestive of an AAM 
subtype, however the mechanisms by which HIF1A mediates changes in macrophage 
differentiation and subsequent fibrosis development remain to be understood and will 
be investigated in this dissertation.  
 
DISSERTATION OVERVIEW 
IPF is a common, chronic disease which significantly impacts the quality of life 
of millions of individuals worldwide(2). Median survival after diagnosis is typically 3-5 
years due to the absence of any effective therapies outside of lung transplantation(26). 
The incidence and prevalence of IPF continues to rise hastening the need to better 
understand the pathways which mediate the development and progression of 
pulmonary fibrosis(5). We have previously demonstrated a role for the signaling 
molecule adenosine in the setting of acute or chronic lung injury and demonstrated its 
elevation in patients with IPF and animal models of bleomycin-induced lung injury(56). 
Activation of ADORA2B by extracellular accumulation of adenosine can lead to 
features of chronic lung disease including inflammation, fibrosis, and tissue 
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remodeling(56).  We have shown previously the increase in expression of ADORA2B 
and AAMs which are correlated with increased pro-fibrotic mediator production(55, 
65). The stabilization of HIF1A has been found to up-regulate ADORA2B however its 
role as a direct modulator of macrophage phenotype remains to be understood (88). 
Additionally, factors which regulate adenosine receptor expression on alternatively 
activated macrophages and their role in IPF are unknown. An understanding of AAMs 
and previous work demonstrating a pro-fibrotic role for ADORA2B receptor led to the 
development of my proposed project which investigates the hypothesis that both 
hypoxia and lung macrophage differentiation contribute to the progression of 
pulmonary fibrosis through up-regulation of ADORA2B; and myeloid-specific 
ADORA2B deletion or HIF1A inhibition in late stages of disease will attenuate 
fibrosis.  
 
Specific Aim 1: Evaluate the expression and regulation of ADORA2B on AAMs 
and determine the role of ADORA2B on AAMs in pulmonary fibrosis.  
Conditional knockout mice lacking ADORA2B receptor on myeloid cells 
(ADORA2Bf/fLysMCre) were exposed to the intraperitoneal bleomycin injections over 
33 days. ADORA2Bf/fLysMCre after bleomycin treatment showed evidenced of 
improved arterial oxygen saturation and decreased fibrosis consistent with the 
presence of fewer AAMs as compared to wild type mice after bleomycin exposure 
(113). To validate these findings in vitro, BMDMs were isolated from C57Bl6 and 
ADORA2B-/- mice, treated with Th2 cytokines and hypoxia in addition to pan-
adenosine receptor agonist, with and without ADORA2B antagonist, to evaluate the 
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effect on AAM and CAM expression along with pro-fibrotic molecule production. 
BMDMs were also utilized to determine the effect of Th1 in comparison to Th2 cytokine 
treatment on adenosine receptor expression. Results of this aim are presented in 
Chapter 3.  
 
Specific Aim 2: Evaluate the expression of HIF1A in AAMs and determine the 
effect of HIF1A inhibition in pulmonary fibrosis.  
 HIF1A stabilization and localization to AAMs in addition to ADORA2B 
expression was characterized in lung sections from patients with IPF. To demonstrate 
HIF1A stabilization in AAMs in a mouse lung sections, Hif1-luciferase reporter mice 
were then exposed to bleomycin. A HIF1A pharmacologic inhibitor, 17-DMAG, was 
then delivered in late stages of bleomycin-induced lung injury in C57BL/6 mice to 
evaluate the role of HIF1A inhibition on ADORA2B expression, macrophage 
differentiation, and the development of fibrosis. Finally, BMDMs from control mice 
were cultured in the presence of a HIF1A stabilizer, inhibitor, STAT6 inhibitor, along 
with genetic silencing to establish the role of HIF1A as a driver of ADORA2B 
expression on macrophages, mediating their differentiation into the AAM subtype, and 
promoting production of pro-fibrotic molecules and the subsequent development of 
pulmonary fibrosis. Chapter 4 discusses the results of this aim.  
 
Specific Aim 3: Evaluate the role of HIF1A on myeloid cells in lung injury.  
 Myeloid-specific HIF1A knockout mice (HIF1Af/fLysMCre) were exposed to 
bleomycin-induced lung injury to evaluate the role of HIF1A in acute and chronic 
47 
 
stages of disease. A time course experiment of varying degrees of bleomycin 
exposure reveal an anti-inflammatory role for HIF1A in acute lung injury. Evaluation 
of fibrotic markers in later stages of disease reveal exacerbations in fibrosis despite 
HIF1A-mediated reductions in ADORA2B and AAM expression. BMDMs from 
HIF1Af/fLysMCre mice were stimulated in culture with Th2 cytokines, hypoxia, and 
adenosine receptor agonist to establish the effect HIF1A deletion on myeloid cells 
places in regulation of ADORA2B and macrophage differentiation.  
Insight into the mechanisms contributing to the development and progression 
of fibrosis in IPF will lead to direct development of novel therapies which target key 
pathways and cells included in this project such as ADORA2B antagonists or HIF1A 
inhibitors which modulate macrophage phenotype, pro-fibrotic mediator production, 
and the development of lung fibrosis.  
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CHAPTER TWO 
 
EXPERIMENTAL PROCEDURES 
Human Subjects 
Explanted lung tissue samples from healthy, normal (n=6) and IPF patients 
(n=19) were de-identified and obtained from the International Institute for the 
Advancement of Medicine (IIAM, Edison, NJ) and the Methodist Hospital J.C. Walter 
Jr. Transplant Center (Houston, TX), respectively (Table I).  These lung tissue are 
those normal or affected lungs that come from lung transplants or lungs gathered but 
not used for transplants. IIAM and Methodist Hospital Institutional Review Board 
guidelines were strictly adhered to for tissue collection and use.  
 
Table I. Distribution of demographic and clinical variables for patient 
population.  
 Normal  
(n=6) 
IPF  
(n=19) 
p-value 
Gender, n (%) 
    Males 
 
1 (16.67) 
 
12 (63.2) 
 
0.00410 
    Females 5 (83.33) 7 (36.8) 0.04362 
Age (Mean ± SD)    
    Overall 43.6 ± 17.07 63 ± 9.22 0.06314 
    Males 63 67 ± 7 0.08801 
    Female 38.75 ± 15.22 56 ± 9.45 0.09926 
BMI (Mean ± SD) 29.46 ± 5.50 28.69 ± 6.24 0.79276 
PaO2, mmHg (Mean ± SD) 138.68 ± 60.44 72.23 ± 29.11 0.07121 
PaCO2, mmHg (Mean ± SD) 37.1 ± 9.20 40.29 ± 6.22 0.49692 
mPAP , mmHg (Mean ± SD)  18.95 ± 6.47  
Systolic PAP, mmHg (Mean ± SD)  30.63 ± 10.36  
Diastolic PAP, mmHg (Mean ± SD)  13.16 ± 5.12  
6MWD, feet (Mean ± SD)  795.24 ± 458.77  
FVC, % (Mean ± SD)  54 ± 24  
DLCO, % (Mean ± SD)  29.06 ± 10.94  
FEV1, % (Mean ± SD)  7.99 ± 3.80  
 
Abbreviations: mPAP = mean pulmonary arterial pressure; PAP = pulmonary arterial 
pressure; 6MWD = six-minute walk distance; BMI = body mass index; FVC = forced vital 
capacity; DLCO = diffusing capacity of the lung for carbon monoxide; TLC = total lung 
capacity; FEV1 = forced expiratory volume in one second; PaO2 = = partial pressure of 
oxygen in arterial blood; PaCO2 = partial pressure of carbon dioxide in arterial blood. 
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Generation and Genotyping of Mouse Lines  
All inbred, male, 5-6 week old C57BL/6 and LysMCre mice were obtained from 
Harlan (Envigo) Laboratories (Houston, TX). ADORA2Bf/fLysMCre, HIF1Af/fLysMCre, 
and Hif1::LUC reporter mice (FVB.129S6-Gt(ROSA)26Sor tm2(HIF1AA/luc)Kael/J) 
were obtained from Holger K. Eltzschig(89). DNA was extracted from tail 
samples to confirm genotypes with PCR. Animals were maintained and cared 
for in agreement with McGovern Medical School at University of Texas Health 
Sciences Center Animal Welfare Committee (AWC) guidelines. Study designs were 
approved by AWC.  
 
Intraperitoneal Bleomycin Mouse Model 
 Bleomycin is a glycopeptide chemotherapeutic antibiotic used to treat different 
types of cancer including testicular cancer and Hodgkin’s lymphoma (114). 10% of 
patients treated develop pulmonary toxicity secondary to reduced levels of the enzyme 
bleomycin hydrolase, responsible for its inactivation (114). Thus, repeated bleomycin 
exposure contributes to inflammation and the subsequent development of pulmonary 
fibrosis(114). Ultimately, bleomycin leads to breaks in the DNA strand contributing to 
the production of ROS(115). C57BL/6 mice are more susceptible to bleomycin-
induced injury and demonstrate increased inflammation in the first 14 to 21 days 
followed by the development of fibrosis by day 20 onwards in an intraperitoneal model 
(56, 115). This model however is limited in that the fibrosis that develops is reversible 
once systemic bleomycin administration is stopped (115). Despite this limitation, the 
bleomycin-induced model of lung injury is more frequently used than exposure to 
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silica, fluorescein isothiocyanate (FITC), or irradiation as it better models features 
observed in patients with IPF including the presence of hyperplastic epithelial cells, 
greater concentration of pleural fibrotic patches, and the fibrosis development is 
progressive (49, 116).  
Utilizing this model, male, 5-6 weeks old, C57BL/6, ADORA2Bf/fLysMCre, 
HIF1Af/fLysMCre, LysMCre, and Hif1::LUC reporter mice were treated with 8 
intraperitoneal bleomycin (0.035U/g, Teva Pharmaceutical, Irvine, CA) or saline 
injections, twice a week over a four week period as described previously (Figure 
2.1A,B,C) (83, 113). HIF1Af/fLysMCre and LysMCre mice were sacrificed and samples 
collected on day 3, 7, 14, 20, and 33. ADORA2Bf/fLysMCre, LysMCre, and C57BL/6 were 
sacrificed and samples collected at the following time points after bleomycin or saline 
exposure: 14, 17, 20, 21, 25, and 33. Samples from Hif1::LUC reporter mice were 
collected on day 33.  
 
In vivo Inhibition of HIF1A 
In vivo inhibition of HIF1A was carried out using 17-
(Dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG, InvivoGen, San 
Diego, CA). Male, 5-6 week old C57BL/6 mice were treated with intraperitoneal 
bleomycin or vehicle control (saline) twice a week for 33 days. Beginning on day 20 
and every other day until day 33, mice were treated with saline (100L 1X sterile PBS) 
or 25mg/kg 17-DMAG(117). Mice received 17-DMAG injections 3-4 hours before 
bleomycin on treatment days were both were to be given. Arterial oxygen saturation 
levels were measured on day 33 prior to animal sacrifice and sample collection.  
51 
 
 
 
Figure 2.1. Intraperitoneal (i.p.) bleomycin model of pulmonary fibrosis. 8 
intraperitoneal bleomycin (0.035U/g, Teva Pharmaceutical, Irvine, CA) or saline 
injections are administered twice a week over a four week period in the i.p. bleomycin 
model. (A) In Chapter 3, samples were collected at day 14, 17, 21, 25, and 33 from 
ADORA2Bf/fLysMCre, LysMCre, and C57BL/6 mice exposed to bleomycin or PBS. (B) 
17-DMAG, an inhibitor of HIF1A, was administered every other day from day 20 
onwards to evaluate the impact of HIF1A inhibition on fibrosis development in Chapter 
4. (C) HIF1Af/fLysMCre and LysMCre mice were sacrificed and samples collected on day 
3, 7, 14, 20, and 33 in Chapter 5. (Red arrows indicate sacrifice and sample collection 
days).  
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Assessment of Arterial Oxygen Saturation 
Mice were shaved along the neck and awake for arterial oxygen saturation 
measurement on day 33 using the Pulse MouseOx software (STARR Life Sciences 
Corp, Oakmount, PA). 
 
Plasma, Bronchoalveolar lavage fluid (BALF), Cellular differentials, and 
Histology 
Once mice were anesthetized with Avertin, blood was collected and centrifuged 
to collect plasma. Lungs were lavaged four times with 0.3mL PBS to collect BALF. A 
hemocytometer was used to determine total cell counts. Aliquots of BAL cells spun 
onto microscope slides and stained with Diff-Quick (Dade Behring, Deerfield, IL) were 
used to assess cellular differentials. BAL fluid remaining was centrifuged and cell 
pellet and supernatant were stored for further analysis. Once BALF was collected, 
lungs were pressure inflated, fixed in 10% formalin, and embedded in paraffin. 5m 
lung sections were used for immunostaining and further histological analysis.   
 
Immunohistochemistry and Immunofluorescence 
Immunohistochemistry was performed on 5m sections from formalin-fixed, 
paraffin-embedded lungs. Antigen retrieval was performed on rehydrated sections 
using Tris-based Antigen Unmasking Solution (Vector Laboratories) followed by 
blocking of endogenous avidin and biotin using the Biotin-Blocking system (Vector 
Laboratories, Burlingame, CA), Bloxall (Vector Laboratories) for 30 minutes, and 
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normal horse serum (Vector Laboratories) for 1 hour at room temperature. Nuclear 
permeabilization with 1% Triton-X 100 was also carried out for 10 minutes after 
antigen retrieval and prior to blocking for anti-HIF1A and anti-firefly luciferase staining. 
Slides for immunohistochemistry were incubated with anti-SMA (1:1000 mouse 
monoclonal; Sigma-Aldrich), anti-CD206 (1:100 rabbit polyclonal; Bioss) , anti-iNOS 
(1:100 rabbit polyclonal; Abcam Inc.), anti-IL-6 (1:100 rabbit polyclonal; Abcam Inc) , 
or anti-Ly6.b (1:500 rat anti-mouse; AbD SeroTec) overnight at 4C and developed 
the following day with the ImmPRESSTM-AP Anti-Rabbit IgG (Alkaline Phosphatase) 
Polymer Detection Kit (Vector Laboratories) prior to counterstaining with 
haematoxylin, dehydration, and mounting with coverslip.  
Dual immunofluorescence staining of F4/80 and CD206 began with primary 
antibody incubation for CD206 (1:100 rabbit polyclonal; Bioss) overnight at 4C, 
development with Vector Red, followed by incubation with F4/80 (1:500 rat polyclonal; 
Acris Antibodies) and development with goat anti-rat Alexa Fluor-488 (1:500; Life 
Technologies). For immunofluorescence staining of alpha smooth muscle actin 
(SMA), slides were incubated with Cy3-conjugated mouse monoclonal anti-SMA 
(1:1000; Sigma-Aldrich) overnight at 4C, prior to mounting with with Vectashield 
Antifade Mounting Medium with DAPI (Vector Laboratories). For dual 
immunofluorescence of HIF1A and CD206, slides were incubated in anti-
HIF1A(1:200 rabbit polyclonal; Bethyl Laboratories Inc.) overnight at 4C and then 
developed using the ImmPRESSTM-AP Anti-Rabbit IgG (Alkaline Phosphatase) 
Polymer Detection Kit described above (Vector Laboratories). Slides were next 
incubated in anti-CD206 (1:100 rabbit polyclonal; Bioss) overnight at 4C prior to 
secondary incubation with Alexa 633 goat anti-rabbit (1:500; Life Technologies) and 
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mounting with Vectashield Antifade Mounting Medium with DAPI (Vector 
Laboratories). Dual immunofluorescence staining of Firefly Luciferase and CD206 
began with primary antibody incubation with Cy3-conjugated anti-firefly luciferase 
(1:1000 rabbit polyclonal; abcam) overnight at 4C, followed by blocking and 
incubation with anti-CD206 (1:100 rabbit polyclonal; Bioss) overnight at 4C. 
Secondary incubation with Alexa 633 goat anti-rabbit (1:500; Life Technologies) was 
carried out at room temperature the next day followed by incubation with sudan black 
for 10 minutes, copper sulfate for 10 minutes, and Levisamole (Vector Laboratories) 
for 5 minutes to quench any autofluorescence and mounting with DAPI (Vector 
Laboratories).  
 
Immunofluorescence of BAL cells 
Cytospun BAL cells from Hif1::LUC reporter mice after saline or bleomycin 
exposure, described above, were air-dried, fixed with 3.7% paraformaldehyde for 10 
minutes, followed by permeabilization in cold methanol for 10 minutes, and nuclear 
permeabilization with 1% Triton-X 100 for 10 minutes. Endogenous avidin and biotin 
were blocked with the Biotin-blocking kit (Vector Laboratories), followed incubation 
with Bloxall (Vector Laboratories) for 10 minutes, and normal horse serum (Vector 
Laboratories) for 20 minutes at room temperature. Slides were then incubated over 
night at 4C with Cy3-conjugated anti-firefly luciferase (1:500, rabbit polyclonal, 
Bioss). After washing with TBS-T, slides were blocked again with Bloxall and normal 
horse serum (Vector Laboratories) before incubation with anti-CD206 (1:500, rabbit 
polyclonal, Bioss) overnight at 4C. The following day, slides were incubated with 
secondary antibody, Alexa Fluor 633 goat anti-rabbit (1:500; Life Technologies) for 
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one hour at room temperature in the dark. Slides were mounted with coverslip and 
Vectashield Antifade Mounting Medium with DAPI (Vector Laboratories).  
 
Assessment of Fibrosis 
Masson’s trichrome collagen staining was performed according to the 
manufacturer’s instructions on rehydrated lung sections (EM Science, Gibbstown, 
NJ). A modified Ashcroft scoring method was used to quantify fibrosis among stained 
slides (118). Slides were blinded to reviewers with respect to treatment group. Soluble 
collagen content in BALF was measured using the Sircol assay (Biocolor Ltd., Carrick, 
UK). Whole lung RNA was used to quantify collagen transcripts and whole lung protein 
lysates utilized for determining fibronectin expression.  
 
Western Blot Analysis 
Mouse lung tissues were pulverized or cells from bone marrow-derived 
macrophages in culture were lysed in RIPA lysis buffer (50mM Tris-HCL pH 7.4, 150 
mM NaCl, 1% NP-40) containing a protease inhibitor cocktail to extract protein 
(Thermo Fisher Scientific, Waltham, MA). Equal amounts of protein were separated 
on SDS-PAGE and transferred to PVDF membranes (GE Healthcare, Life Sciences, 
Pittsburgh, PA). Membranes were blocked for 1 hour at room temperature with 5% 
nonfat milk and then washed with Tris-buffered saline-Tween-20 and incubated with 
primary HIF1A (1:500 rabbit polyclonal; LifeSpan Biosciences), ADORA2B (1:1000 
rabbit polyclonal; LifeSpan Biosciences), CD206 (1:250 rabbit polyclonal; Bioss), 
fibronectin (1:1000 rabbit polyclonal; Sigma-Aldrich), collagen I (1:1000 rabbit 
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polyclonal; abcam), -actin (1:1000 rabbit polyclonal) overnight at 4C. Washed 
membranes were incubated with corresponding secondary antibodies conjugated to 
horseradish peroxidase (Cell Signaling Technology, Danvers, MA, USA) for 1 hour at 
room temperature and developed with Amersham ECL Prime Western Blotting 
Direction Agent (GE Healthcare, Life Sciences) or Pierce ECL Western Blotting 
Substrate (Thermo Fisher Scientific). 
 
Analysis of whole lung and BAL cell pellet RNA 
RNA was isolated from frozen lung tissue, bronchoalveolar lavage cell pellet, 
or macrophage cell lysate using TRIzol (Invitrogen) as per manufacturer’s instructions. 
cDNA was synthesized using the iScriptTM cDNA synthesis kit (BioRad) and equal 
amounts were analyzed for transcript levels of COL1A1, COL1A2, ARG-1, ADORA2B, 
NOS2, IL-6, and CXCL1 with normalization to beta actin or 18s rRNA. Primers for 
COL1A1 were forward 5’-GCTCCTCTTAGGGGCCACT-3’ and reverse 5’-
CCACGTCTCACCATTGGGG-3’. Primers for COL1A2 were forward 5’-
AAGGGTGCTACTGGACTCCC-3’ and reverse 5’-TTGTTACCGGATTCTCCTTTGG-
3’. Primers for ARG-1 were forward 5’-CAGAAGAATGGAAGAGTCAG-3’ and reverse 
5’-CAGATATGCAGGGAGTCACC-3’. Primers for ADORA2B were forward 5’-
GCGTCCCGCTCAGGTATAAAG-3’ and reverse 5’- 
CGGAGTCAATCCAATGCCAAAG-3’. Primers for NOS2 were forward 5’-
GTTCTCAGCCCAACAATACAAGA-3’ and reverse 5’-GTGGACGGGTCGATGTCA-
3’. Primers for IL-6 were forward 5’-TAGTCCTTCCTACCCCAATTTCC-3’ and reverse 
5’-TTGGTCCTTAGCCACTCCTTC-3’. Primers for CXCL1 were forward 5’-
CTGCACCCAAACCGAAGTC-3’ and reverse 5’-AGCTTCAGGGTCAAGGCAAG-3’. 
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Primers for MCP-1 were: forward 5’-TCAGCCAGATGCAGTTAACGC-3’ and reverse 
5’-TGATCCTCTTGTAGCTCTCCAGC-3’. Next, the comparative Ct method was used 
to present data as mean normalized transcript levels.  
 
Quantification of Protein in Bronchoalveolar Lavage Fluid 
IL-6 levels in BALF from C57BL/6 and ADORA2Bf/fLysMCre mice after 
bleomycin or PBS treatment was quantified using the murine IL-6 ultrasensitive kit 
(Meso Scale Discovery) and read on the Sector Imager 2400 (Meso Scale Discovery) 
per manufacturer’s protocol. Collagen levels were assessed in BALF from C57BL/6 
mice after PBS or BLM exposure ± 17-DMAG on day 33 utilizing the BioColor kit per 
manufacturer’s instructions. The Mouse ELISA Kit from Immunology Consultants 
Laboratory was used to quantify albumin levels and Hycult Biotech ELISA Kit to 
assess MPO levels in BALF from HIF1Af/fLysMCre and LysMCre mice after PBS or BLM 
exposure on day 3 and 7.   
 
Dual-luciferase Assay 
Whole lung lysate and BALF from Hif1::LUC reporter mice after saline or 
bleomycin treatment was prepared for luciferase activity measurement per 
manufacturers protocol (Dual-Luciferase Reporter Assay System, Promega 
Corporation, Madison, WI). Briefly, samples were diluted in Passive Lysis Buffer (PLB, 
Promega), protein concentration measured using the PierceTM BCA Protein Assay Kit 
(ThermoFisher Scientific), and samples were diluted to 0.5g/uL of PLB in a 96-well 
plate. Equal volumes of Luciferase Assay Reagent II (LAR, Promega) were added to 
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each well prior to measurement of Firefly luciferase activity, followed by addition of 
equal volumes of Stop & Glo Reagent (Promega) to each well and Renilla luciferase 
activity. Data are presented as relative luciferase activity, or Firefly luciferase to 
Renilla luciferase activity. 
 
Bone Marrow Macrophage Isolation and Differentiation 
Bilateral femurs were isolated from male C57BL/6 mice (5-6 wk old, inbred, 
Envigo Laboratories). Complete macrophage medium, DMEM (Fisher Scientific) 
supplemented with 10% FBS and 20% L929 media supplement was next used to flush 
the marrow cavity. L929 media supplement was made by seeding L929 cells at a 
density of 5x105 cells per T75 flask in 55mL media of DMEM with 1% HEPES, 1% 
penicillin-streptomycin, 1% L-glutamine, and 10% FBS. L929 cells were then cultured 
for 7 days and harvested media was sterile filtered for addition to macrophage culture 
media. Bone marrow cells were pelleted, resuspended in complete macrophage 
media and plated in 100mm bacterial dishes at a density of 5x106 cells in 10mL media 
per dish. Cells were incubated at 37°C, 5% CO2 for 4 days and then supplemented 
with 5mL of media. On day 7, adherent bone marrow-derived macrophages were 
detached, collected, pelleted, and resuspended in macrophage media for seeding in 
six-well tissue culture plates at a density of 1.5x106 cells/mL and allowed to adhere 
for 2-3h. Adherent cells were then incubated in macrophage media with and without 
20ng/mL Interleukin 4 (IL-4) and 10ng/mL Interleukin-13 (IL-13) (Peprotech, Rocky 
Hill, NJ) for three days with addition of fresh cytokines daily or 100ng/mL LPS (Sigma) 
and 30ng/mL IFN(PeproTech) for 24 hours. Macrophages were washed and used 
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for ADORA2A, ADORA2B, STAT-6, and HIF1A stimulation and antagonism 
experiments (Figure 2.2).  
 
Figure 2.2 Bone marrow derived macrophages isolation, culture, and treatment. 
Bone marrow (BM) cells were isolated from femurs of C57BL/6 (A,B), (A) ADORA2A-
/-, ADORA2B-/-, HIF1Af/fLysMCre, and LysMCre mice and cultured with L929-
supplemented media for 7 days. In Chapter 3 (denoted (3)), these macrophages were 
then treated with (A) 10ng/mL IL-4 and 10ng/mL IL-13 for 72 hours or (B) 100ng/mL 
LPS and 30ng/mL IFN for 24 hours followed by 12 hour 2% O2 exposure alongside 
treatment with NECA ± MRS1754 and NECA ± ZM241385. In Chapter 4 (4), C57BL/6 
BMDMs were treated with CoCl2 ± 17-DMAG at time 0hr or double-transfected with 
control or siRNA against HIF1A on -2d and -1d prior to hypoxia exposure. In Chapter 
5 (5), HIF1Af/fLysMCre and LysMCre BMDMs were treated with NECA and C57BL/6 
BMDMs were double transfected with control siRNA, siRNA against HIF1A and HIF2A 
on -2d and -1d. Cells were lysed and RNA and protein collected at 12hours (12h).  
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Primary Lung Macrophage and Isolation 
Mouse lungs from male C57BL/6 mice exposed to bleomycin over 33 days, as 
described above, were isolated and treated with 1 to 2mL Dispase (BD Bioscience, 
San Jose, CA, USA) and immediately stored on ice. The lungs were then incubated 
in 2mL Dispase at room temperature for 45 minutes, diced into 1mm cubes and filtered 
through 100m, 40m, and a 25m nylon mesh. Filtered cells were incubated in an 
IgG plate for 45 minutes at 37C in lung macrophage media (RPMI 1640 (Fisher 
Scientific), 10% FBS, and 1% penicillin/streptomycin) to select for macrophages. Cells 
were washed in fresh macrophage media to remove detached cells or other cell-types 
and allow for macrophages to settle prior to treatment with CoCl2 and 17-DMAG.  
 
Stimulation and Antagonism of Adenosine Receptors, STAT-6, AND HIF1A in 
Macrophages 
Bone marrow-derived macrophages treated with and without IL-4/IL-13 for 72 
hours, were next incubated in serum-free media for up to 12 hours. Macrophages were 
pre-incubated with Adenosine deaminase (PEG-ADA; Roche) to inhibit endogenous 
adenosine activity prior to 12 hour hypoxia exposure, 2% O2, and treatment with 10m 
1-(6-Amino-9H-purin-9-yl)-1-deoxy-N-ethyl--D-ribofuranuronamide (NECA, Tocris 
Bioscience, Minneapolis, MN) or 1m Bay 60-6085 (Tocris Bioscience, Minneapolis, 
MN) with and without 1m N-(4-Cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-
dipropyl-1H-purin-9-yl)phenoxy]-acetamide (MRS 1754, Tocris Bioscience, 
Minneapolis, MN) to stimulate and antagonize ADORA2B; 10M ZM241385 (Tocris 
Bioscience) to stimulate and antagonize ADORA2A; 100nM AS 1517499 (axon 
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MEDCHEM, Netherlands) to inhibit STAT-6; 3m 17-DMAG with and without 100m 
CoCl2 (Sigma-Aldrich) to stabilize and antagonize HIF1AAfter 12 hours exposure 
with the above treatments, macrophages were lysed in RIPA lysis buffer (20g of 
protein per sample) or TRIzol (Invitrogen) for western blot and RNA analysis, 
respectively. 
 
HIF1A and HIF2A Small Interfering RNA Silencing in Macrophages 
Bone marrow derived macrophages from day 7-8 were resuspended in 
antibiotic-free macrophage media, seeded in 6-well plates, and allowed to adhere for 
2-3 hours. Macrophages were then incubated in media containing IL-4, IL-13, 
Optimem (Invitrogen) with Lipofectamine RNAiMax (Invitrogen), HIF1A siRNA and or 
HIF2A siRNA, or scrambled control siRNA (Sigma-Aldrich) for 24 hours. Final 
concentration of siRNA was 100nM. 24 hours later, media was changed and the 
transfection was repeated with fresh reagents for another 24 hours prior to hypoxia 
exposure (2% O2) for 12 hours. Cells were lysed in RIPA lysis buffer with protease 
inhibitors for western blot analysis (20g of protein per sample) or TRIzol reagent 
(Invitrogen) and processed for RNA analysis as described above. 
 
Statistical Analysis 
Experiments were repeated at least two times with biological and technical 
duplicates at minimum. One-way ANOVA was used for comparisons among multiple 
groups. Unpaired, two-tailed Student’s t-test was used for comparisons between two 
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groups. A p-value of less than or equal to 0.05 was considered statistically significant. 
All statistical analyses were performed with GraphPad Prism 6.0 software (La Jolla, 
CA).   
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CHAPTER THREE 
ADORA2B ON MYELOID CELLS CONTRIBUTES TO THE DEVELOPMENT OF 
PULMONARY FIBROSIS 
INTRODUCTION 
Note: This chapter is based upon: Karmouty-Quintana H., K. Philip, L.F. Acero, N.Y. 
Chen, T. Weng, J.G. Molina, F. Luo, J.Davies, N.B.Le, I. Bunge, K.A. Volcik, T.T. Le, 
R.A. Johnson, Y.Xia, H.K. Eltzschig, and M.R. Blackburn. 2015. Deletion of ADORA2B 
from myeloid cells dampens lung fibrosis and pulmonary hypertension. FASEB 
journal: official publication of the Federation of American Societies for Experimental 
Biology 29: 50-60. http://www.fasebj.org/content/29/1/50.full Copyright permission 
granted 06 Feb 2017 for FJ 14-260182.  
 
Adenosine Signaling on AAMs in IPF 
Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease which 
affects up to 8 million individuals worldwide (2-4). Despite its significant prevalence, 
little is known about the mechanisms that lead to the development and progression of 
IPF(15). There are few effective treatments for IPF and the five year survival rate 
among patients with IPF is only 43%(28). Prognosis in IPF patients is poor secondary 
to few effective long-term therapies. As such, there is a significant need to better 
understand the pathogenesis of IPF in order to develop novel pharmaceutical 
therapies to prevent and reverse this disease. 
Previous work suggests that pulmonary fibrosis results from an abnormal tissue 
reparative response(53). Evidence suggests that the nucleoside adenosine plays a 
critical role in the regulation of this response in the lung and contributes to fibrosis (52, 
55, 119). Adenosine levels are elevated in patients with IPF and mouse models of 
lung injury in association with increased inflammation and fibrosis(55, 56). Chronic 
adenosine accumulation and subsequent activation of ADORA2B can lead to features 
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of chronic lung disease including inflammation, fibrosis, and tissue remodeling (56).  
There is evidence that the key effector cell type influenced by ADORA2B receptor 
signaling in pulmonary fibrosis is the pro-fibrotic AAM subtype, typically activated by 
Th2 cytokines, IL-4 and IL-13 (94, 113). Recent work also suggests ADORA2B 
mediates differentiation of macrophages into the AAM phenotype (48, 108).  
 
Experimental Rationale  
Previous work by our lab has shown that IPF patients have increased ADORA2B 
receptor positive alternatively activated macrophages (AAM) and we have also shown 
that the presence of the ADORA2B receptor on these macrophages is critical to the 
production of pro-fibrotic cytokines such as interleukin-6 (IL-6)(55, 56). In this chapter, 
a myeloid-specific ADORA2B knockout mice is exposed to bleomycin along with bone 
marrow-derived macrophages to investigate the hypothesis that ADORA2B on 
myeloid cells mediates differentiation of macrophages into the AAM subtype, 
increases pro-fibrotic mediator production, and the subsequent development and 
progression of pulmonary fibrosis.  
 
RESULTS 
Deletion of ADORA2B on myeloid cells attenuates pulmonary fibrosis in 
association with improved arterial oxygen saturation  
 We have previously demonstrated an increase in ADORA2B-expressing AAMs 
in patients with IPF, however the role of this receptor on myeloid-cells in contributing 
to pulmonary fibrosis remains to be understood (55). As such, we utilized the well-
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established intraperitoneal bleomycin model of chronic lung disease to evaluate how 
genetic deletion of ADORA2B on myeloid cells would impact the development of 
fibrosis. C57BL/6, LysMCre, and ADORA2Bf/fLysMCre mice were treated with intra-
peritoneal bleomycin or saline for 14, 17, 21, 25, and 33 days. On day 33, whole lung 
lysate and lung sections were isolated to assess fibrotic markers. Fibronectin protein 
expression (Figure 3.1 A,B) were increased in C57BL/6 exposed to bleomycin but 
reduced in myeloid-specific ADORA2B knockout mice after bleomycin exposure. 
Collagen 1A2 transcript levels, another marker of fibrosis, was increased after 
bleomycin exposure in control mice but significantly reduced in mice lacking 
ADORA2B on myeloid cells treated with bleomycin (Figure 3.1C). 
Immunohistochemistry of lung sections for alpha-smooth muscle actin (SMA), a 
marker of myofibroblasts, demonstrated an increase in myofibroblasts after bleomycin 
exposure which was attenuated in ADORA2Bf/fLysMCre after bleomycin treatment 
(Figure 3.1D). Masson’s Trichrome staining for collagen in whole lung sections was 
also decreased in ADORA2Bf/fLysMCre mice after bleomycin exposure as compared 
to wild-type control mice, C57BL/6, after 33 days of bleomycin treatment; the Ashcroft 
scoring method was used to quantify these histologic findings over multiple lung 
sections from each treatment group (Figure 3.2A,B).  
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Figure 3.1. Myeloid-specific ADORA2B deletion attenuates fibrotic markers on 
day 33 after BLM or PBS exposure. [Adapted from Figure 1 of (113)]. (A) 
Immunoblot for fibronectin and -actin in whole-lung lysates from C57BL/6 mice 
treated with PBS or BLM and ADORA2Bf/fLysMCre mice treated with BLM with 
densitometry analysis (B).  (C) Col1A2 mRNA expression levels from C57BL/6 mice 
treated with PBS or BLM or ADORA2Bf/fLysMCre mice exposed to PBS or BLM. D) 
Immunohistochemistry for alpha-smooth muscle actin (SMA) with Gill’s hematoxylin 
counterstain from formalin-fixed paraffin-embedded (FFPE) lung sections from 
ADORA2Bf/fLysMCre mice exposed to PBS (left), C57BL/6 mice exposed to BLM 
(middle),or ADORA2Bf/fLysMCre mice treated with BLM (right). (Positive staining for 
SMA is red/pink; Black arrows point at fibroblasts positive for SMA.) (A-C) Used 
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with permission from Ning-Yuan Chen and Harry Karmouty-Quintana who performed 
immunoblot, PCR, and assembled data, respectively. ***P ≤ 0.001, ANOVA 
comparisons between C57BL/6 + PBS and C57BL/6 + BLM treatment groups. #P ≤ 
0.05 and ##0.001, P ≤ 0.01, ANOVA comparisons between C57BL/6-BLM and 
ADORA2Bf/fLysMCre + BLM treatment groups. Collagen 1a2 mRNA expression 
assessed using real-time PCR. Data presented as %-actin. Images are 
representative of n ≥ 4 animals from each group. Scale bar, 200 mm. 
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Figure 3.2. Myeloid-specific ADORA2B deletion attenuates development of 
pulmonary fibrosis after BLM treatment [Adapted from Fig.2 and Fig 3. of (113)]. 
(A) Masson’s Trichrome collagen staining in whole lung sections with quantitative, 
fibrotic histologic scores as given by (B) Ashcroft scores in C57BL/6 and 
ADORA2Bf/fLysMCre mice after 33-day i.p. PBS or Bleomycin. (C) Arterial oxygen 
saturation in C57BL/6 and ADORA2Bf/fLysMCre mice after PBS or BLM treatment. (A-
C) Used with permission from Ning-Yuan Chen who performed Trichrome staining and 
Harry Karmouty-Quintana who performed pulse oximetry measurements and 
assembled data. Results are presented as mean ± SEM, n = 5-7. ***P < 0.001, **0.001 
< P < 0.01, and *P < 0.05, comparisons between C57BL/6 + PBS and C57BL/6 + BLM 
treatment groups. ###P < 0.001 and #P < 0.05, ANOVA comparisons between C57BL/6 
+ BLM and ADORA2Bf/fLysMCre + BLM groups. Images are representative of n ≥ 4 
animals from each group. Scale bar: 200μm (4x). 
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This reduction in fibrotic endpoints in mice lacking ADORA2B on myeloid cells after 
bleomycin treatment were in association with improved arterial oxygen saturation as 
compared to bleomycin treatment of C57BL/6 mice (Figure 3.2C). These findings 
ultimately indicate myeloid-specific deletion of ADORA2B in a bleomycin-induced 
model of lung fibrosis can attenuate pulmonary fibrosis, suggesting a role for 
ADORA2B on myeloid cells as a therapeutic target. 
 
BLM exposure of myeloid-specific ADORA2B knockout mice yields reductions 
in AAMs and subsequent pro-fibrotic mediator production 
To distinguish the changes in macrophage cell type after bleomycin exposure 
in ADORA2Bf/fLysMCre mice, lung sections were evaluated for CD206 expression, a 
marker of AAMs. Immunostaining for CD206 and semi-quantification of CD206+ 
macrophages over time showed a decrease in AAMs in bleomycin-treated 
ADORA2Bf/fLysMCre mice as compared to C57BL/6 mice after bleomycin exposure 
(Figure 3.3A,C). Co-immunofluorescence for pan-macrophage murine marker, F4/80, 
and CD206 also revealed a decrease in F4/80+CD206+ macrophages (yellow signal) 
in myeloid-specific ADORA2B knockout mice after bleomycin exposure as compared 
to C57BL/6 mice (Figure 3.3B). No significant difference was observed however in 
iNOS+ macrophages, a marker for the classically-activated macrophage (Figure 
3.4A,B). These data reveal the attenuation in fibrosis is due to the absence of 
ADORA2B on myeloid cells reducing AAM expression with no effect on CAMs. 
Interleukin-6 (IL-6) is a key pro-fibrotic mediator known to be released by 
macrophages after activation of ADORA2B(55). IL-6 levels were found to be 
significantly increased as early as 14 days after bleomycin exposure and continued to 
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increase by day 33 in bronchoalveolar lavage fluid (BALF) from C57BL/6 mice. 
However, these levels were significantly reduced in ADORA2Bf/fLysMCre mice after 
bleomycin treatment on days 25 and 33 (Figure 3.5A). Immunohistochemistry for IL-6 
shows fewer IL-6 positive macrophages on day 33 in ADORA2Bf/fLysMCre mice after 
bleomycin treatment as compared to control mice, supporting the observed changes 
in IL-6 levels in BALF (Figure 3.5B). 
 
 
Figure 3.3 Fewer AAMs are observed on day 33 after treatment with BLM or PBS 
in myeloid-specific ADORA2B knockout mice [Adapted from Figure 7 and 
Supplemental Figure 2 of (113)]. (A) Quantification of CD206+ macrophages identified 
morphologically from CD206-stained sections from C57BL/6 + BLM, C57BL/6 + PBS, 
and ADORA2Bf/fLysMCre + BLM and ADORA2Bf/fLysMCre + PBS groups at 14, 21, 25, 
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and 33 d of treatment. (B) Double immunofluorescence for F/480 (green signals) or 
CD206 (red signals) from C57BL/6 mice exposed to BLM (left) and LysMCre mice 
exposed to BLM (right) on day 33. White arrows indicate cells that express both F4/80 
and CD206 (cells that co-localize F4/80 and CD206 appear yellow). White asterisks 
represent cells that only express F4/80. (C) Immunohistochemistry for CD206 from 
formalin-fixed paraffin-embedded (FFPE) lung sections from C57BL/6 + PBS (left) 
ADORA2Bf/fLysMCre + PBS (left middle), C57BL/6 + BLM mice (right middle), or 
ADORA2Bf/fLysMCre + BLM (right) at day 21 (upper row) or day 33 (bottom row). 
Positive staining for CD206 is red/pink; sections were counterstained with Gill’s 
hematoxylin. Black arrows point at macrophages positive for CD206. ***P < 0.001 and 
**0.001 < P < 0.01, ANOVA comparisons between C57BL/6 + PBS and C57BL/6 + 
BLM treatment groups. #P < 0.01, ANOVA comparisons between C57BL/6 + BLM and 
ADORA2Bf/fLysMCre + BLM treatment groups. Images are representative of n ≥ 4 
animals from each group. Scale bar, 200 m.  
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Figure 3.4. Classically-activated macrophages 33 days after BLM or PBS 
exposure in myeloid-specific ADORA2B knockout mice. (A) 
Immunohistochemistry for iNOS from formalin-fixed paraffin-embedded (FFPE) lung 
sections from C57BL/6 + PBS (left), C57BL/6 + BLM mice (middle), or 
ADORA2Bf/fLysMCre + BLM (right) on day 33. Positive staining for iNOS is red/pink; 
sections were counterstained with methylgreen. (B) Quantification of iNOS+ 
macrophages identified morphologically from iNOS-stained sections from C57BL/6 + 
BLM, C57BL/6 + PBS, and ADORA2Bf/fLysMCre + BLM and ADORA2Bf/fLysMCre + 
PBS groups at 14, 21, 25, and 33 d of treatment. Images are representative of n ≥ 4 
animals from each group. Scale bar, 200 m. 
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Figure 3.5. IL-6 levels are reduced in ADORA2Bf/fLysMCre mice after BLM 
exposure [Adapted from Fig.8 of (113)]. (A) IL-6 levels in BALF from C57BL/6 mice 
exposed to BLM or PBS and ADORA2Bf/fLysMCre mice treated with BLM or PBS at 14, 
17, 21, 25, and 33 d after treatment. Immunohistochemistry for IL-6 (B) showing 
positive staining for IL-6 (red/pink signals) in macrophages (arrowheads) from a 
C57BL/6 mouse (left) or an ADORA2Bf/fLysMCre mouse (right) treated with BLM. (A) 
Used with permission from Ning-Yuan Chen who performed ELISA for IL-6. Results 
are presented as mean ± SEM. *P < 0.05 and **0.001 < P < 0.01, comparisons between 
C57BL/6 + PBS and C57BL/6 + BLM treatment groups. #P < 0.05 and ##0.001 < P < 
0.01, ANOVA comparisons between C57BL/6 + BLM and ADORA2Bf/fLysMCre + BLM 
groups.  
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ADORA2B mediates hypoxia-induced macrophage differentiation and 
production of pro-fibrotic mediators in BMDMs 
The data above demonstrate that the absence of ADORA2B on myeloid cells 
in bleomycin exposure, reduces AAM expression, and subsequent pro-fibrotic 
mediator production. To further clarify the role of ADORA2B in mediating macrophage 
differentiation in a robust, in vitro BMDM system, BMDMs were isolated from wild-type 
(C57BL/6) and mice with global ADORA2B deletion (ADORA2B-/-) prior to IL-4/IL-13 
co-treatment with hypoxia exposure. ADORA2B-/-  BMDMs no longer showed robust 
increases in Arginase-1 expression or subsequent pro-fibrotic mediator, IL-6, 
expression supporting a role for ADORA2B in mediating differentiation of 
macrophages into the pro-fibrotic alternatively-activated subtype as described 
previously (Figure 3.6A, 3.7C)(48, 108). Similarly, treatment with a pan-adenosine 
receptor agonist, 10M NECA, led to significant increases in Arginase-1 expression 
and subsequent pro-fibrotic mediators, IL-6 and CXCL1, which were reduced in the 
presence of an ADORA2B-specific antagonist, 1M MRS 1754 (Figure 3.6B, 3.7A, B). 
However, genetic deletion of ADORA2B in the presence of Th1 cytokines, 
lipopolysaccharide (LPS) and interferon-gamma (IFN), showed no significant 
difference in classically-activated macrophage (CAM) marker, iNOS, expression 
(Figure 3.6C) highlighting the importance and supporting in vivo data above of 
ADORA2B in mediating macrophage differentiation into AAMs but not CAMs. These 
data reveal the importance of ADORA2B on macrophages in mediating their 
differentiation into the pro-fibrotic AAM after hypoxia exposure, and further highlight a 
role for ADORA2B antagonists in treatment of pulmonary fibrosis.   
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Figure 3.6. Absence or antagonism of ADORA2B disrupts macrophage 
differentiation into AAMs. C57Bl6  and (A,C) ADORA2B-/- BMDMs were polarized 
with IL-4 and IL-13 for 72 hours and then incubated in hypoxia (2% O2) for 12 hours 
in the presence of (B) 10M NECA, 1M MRS1754, or (C) 100ng/mL 
lipopolysaccharide (LPS) with 30ng/mL interferon-gamma (IFN) treatment. (A,B) 
Arginase-1 and (C) iNOS, mRNA expression was assessed using real-time PCR. Data 
presented as %-actin. ***p < 0.001, **0.001 < p < 0.01, and *p < 0.05, ANOVA 
comparisons between treatment groups. 
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Figure 3.7. Absence or antagonism of ADORA2B disrupts pro-fibrotic mediator 
production. (A-C) C57Bl6  and  (C) ADORA2B-/- BMDMs were polarized with IL-4 and 
IL-13 for 72 hours and then incubated in hypoxia (2% O2) for 12 hours in the presence 
of (A-C) 10M NECA or (A,B) 1M MRS1754. (A, C) Interleukin-6 and (B) CXCL1 
mRNA expression was assessed using real-time PCR. Data presented as %-actin. 
***p < 0.001 and **0.001 < p < 0.01, ANOVA comparison between IL-4/13 + hypoxia ± 
NECA treatment vs NECA ± MRS treatment. 
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DISCUSSION 
 ADORA2B has been shown extensively to mediate pro-fibrotic effects in 
pulmonary fibrosis (56). Despite its expression throughout various cell types in the 
lung as demonstrated through in-situ hybridization previously, work by Zhou et al. 
have  illustrated an elevation in ADORA2B-expressing, CD206+ macrophages in IPF 
patients and animal models of bleomycin exposure(55, 64). Our studies demonstrate 
myeloid-specific ADORA2B deletion followed by bleomycin exposure yields 
reductions in pulmonary fibrosis in association with reduced AAM expression and 
improved arterial oxygen saturation. A role for ADORA2B in mediating macrophage 
differentiation into the pro-fibrotic AAM and subsequent pro-fibrotic mediator 
production was illustrated in vitro using ADORA2B genetic deletion and 
pharmacologic agonism and antagonism in BMDMs. In accord with previously 
published work, ADORA2B deletion in vivo after bleomycin treatment and in vitro 
BMDM work revealed ADORA2B does not mediate differentiation of macrophages 
into the classically activated pro-inflammatory phenotype. Together, these data 
suggest a clinically significant role for myeloid-specific ADORA2B antagonists in 
treating patients with IPF.   
This work emphasizes the role of ADORA2B on myeloid cells in mediating the 
development of pulmonary fibrosis through a mouse model of bleomycin-induced lung 
fibrosis and in vitro bone marrow derived macrophage system. Bleomycin treatment 
of mice lacking ADORA2B on myeloid cells resulted in decreased pulmonary fibrosis 
as evidenced by reductions in fibrotic extracellular matrix proteins including fibronectin 
and collagen. Decreases in lung fibrosis were associated with fewer CD206+ AAMs 
in late stages of disease as assessed in lung sections along with significant 
78 
 
improvements in arterial oxygen saturation. These data further support a key role for 
AAMs in mediating fibrosis and remodeling in the lung. Although fibrosis was 
attenuated with myeloid-specific ADORA2B deletion, it was not completely eradicated 
pointing to the importance of other cell-types which may also express ADORA2B in 
mediating the development and progression of pulmonary fibrosis. As such, further 
work includes delineating the contribution of other cell types in the lung by exposing 
conditional knock-out mice for type 1 or type 2 epithelial cells to bleomycin, separately 
or in combination with myeloid-specific deletion.  
A key finding of this work includes demonstrating the role of ADORA2B on 
mediating differentiation of macrophages into the AAM subtype. AAM marker 
expression was increased in control BMDMs after hypoxia and Th2 cytokine exposure 
but significantly decreased in those BMDMs from ADORA2B-deficient mice. 
Pharmacologic antagonism of ADORA2B in BMDMs also led to disruption of AAM 
expression as well, in addition to a significant reduction in production of pro-fibrotic 
mediators, including IL-6 and CXCL1. Of note however, genetic deletion of ADORA2B 
on BMDMs did not inhibit differentiation of macrophages into the classically-activated 
macrophage subtype in the presence of Th1 cytokines, IFN and LPS. In fact, Th1 
cytokine treatment and hypoxia exposure of BMDMS instead leads to robust increase 
in the ADORA2A receptor (Figure 3.8A) while Th2 cytokine treatment contributes to 
statistically significant increases in ADORA2B mRNA transcripts as compared to 
ADORA2B (Figure 3.8B,C). ADORA3 is known to mediate anti-inflammatory effects 
and predominantly expressed in peripheral mononuclear cells and as such, the 
increased expression in BMDMs as compared to other adenosine receptors is 
expected (Figure 3.8B)(120). In fact, we have previously shown that bleomycin 
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exposure in a global ADORA3-/- leads to no significant differences in pulmonary 
fibrosis as compared to control ADORA3+/+ mice despite initial increases in 
inflammatory markers indicating a role for ADORA3 in regulating anti-inflammatory 
features of acute lung injury(69).  
In the presence of IL-4 and IL-13 treatment however, both ADORA2B and to a 
lesser extent, ADORA2A, mediate differentiation of macrophages to AAMs and 
inhibition of these receptors reduce pro-fibrotic mediator production as evidenced by 
reductions in Arginase-1 and IL-6 expression with global deletion of ADORA2A or 
ADORA2B from BMDMs (Figure 3.9A,B) or pharmacologic antagonism in control 
BMDMs (Figure 3.9C,D).  
These findings support work by Hasko et al. which illustrate a role for 
ADORA2B activation in augmenting the AAM phenotype with production matrix 
remodeling and anti-inflammatory mediators in addition to ADORA2A activation as a 
means to promote the pro-inflammatory CAM population by suppressing production 
of tumor necrosis factor- (TNF), interleukin-12, and nitric oxide(48, 108). Further 
work includes validating the observations above in lung macrophages isolated from 
bleomycin-treated mice in addition to lung macrophages from patients with and 
without IPF. 
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Figure 3.8. T-helper cell cytokine treatment and hypoxia exposure alters 
adenosine receptor expression. BMDMs were isolated from C57Bl6 mice. On day 
7, macrophages were polarized with (A) 100ng/mL LPS and 30ng/mL IFN for 24 
hours or (B,C) 10ng/mL IL4 and 10ng/ml IL-13 for 72hrs followed by serum starvation 
for 12hrs.  PEG-ADA added 30min prior to incubation at 37C in 21% O2 or 2% O2 for 
12 hours. Results represent pooled data from biological duplicate experiments. 
ADORA1, ADORA2A, ADORA2B, and ADORA3 mRNA expression assessed using 
real-time PCR. Data presented as %-actin.  
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Figure 3.9. ADORA2A and ADORA2B mediate macrophage differentiation and 
pro-fibrotic mediator production. BMDMs from C57BL/6, ADORA2A-/-, and 
ADORA2B-/- mice were polarized with 10ng/mL IL4 and 10ng/ml IL-13 for 72hrs 
followed by serum starvation for 12hrs.  PEG-ADA added 30min prior to treatment 
with 10M NECA, 10M ZM 241385, or 1M MRS 1754. PEG-ADA added 30min prior 
to incubation at 37C in 21% O2 or 2% O2 for 12 hours. Results represent pooled data 
from biological duplicate experiments. Arginase-1 and Interleukin-6 mRNA expression 
assessed using real-time PCR. Data presented as %-actin.  
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Together, these data demonstrate the role of ADORA2B on myeloid cells in a 
bleomycin-induced model of pulmonary fibrosis. They demonstrate that bleomycin 
treatment of mice lacking ADORA2B on myeloid cells leads to reductions in AAMs in 
association with improved pulmonary function. These results are supported by in vitro 
data in BMDMs which reveal the importance of ADORA2B itself in mediating 
differentiation of macrophages to the AAM phenotype in the presence of both hypoxia 
and a Th2 cytokine rich environment. Chapter 4 assesses the contribution of hypoxia 
itself through the hypoxia inducible factor 1A (HIF1A) transcription factor in regulating 
ADORA2B expression, macrophage differentiation, and the development of 
pulmonary fibrosis utilizing pharmacologic inhibition in an in vivo model along with 
BMDMs. Chapter 5 examines the effects of myeloid-specific HIF1A deletion on 
pulmonary fibrosis development revealing a role for HIF1A in acute stages of lung 
injury.  
 
 
 
 
 
 
 
 
 
83 
 
CHAPTER FOUR 
HIF1A UPREGULATES THE ADORA2B RECEPTOR ON ALTERNATIVELY 
ACTIVATED MACROPHAGES AND CONTRIBUTES TO PULMONARY FIBROSIS 
 
INTRODUCTION 
Note: This chapter is based upon: Philip K, Mills T, Davies J, Chen NY, Karmouty-
Quintana H, Luo F, Molina JG, Amione-Guerra J, Sinha N, Guha A, Eltzschig HK, and 
Blackburn MR. HIF1A Up-regulates the ADORA2B receptor on Alternatively Activated 
Macrophages and Contributes to Pulmonary Fibrosis. Under Review.  
 
In the preceding chapter, we provide evidence that activation of ADORA2B on 
myeloid cells contributes to the development of lung fibrosis by promoting 
macrophage differentiation into the pro-fibrotic AAM phenotype in a bleomycin-
induced model of chronic lung disease(113). In support of these findings, antagonism 
of ADORA2B on BMDMs yields reduced AAM expression and subsequent reductions 
in pro-fibrotic mediators including interleukin-6 and CXCL1. However, the disease 
signals leading to this are unknown, thereby limiting the development of targeting 
therapies for IPF.  
 
Hypoxia and Adenosine Signaling 
We hypothesized that hypoxia may be the driver of changes in ADORA2B and 
AAMs in IPF. Hypoxia, or low oxygen supply, is common in IPF patients and is known 
to regulate elements of the adenosine pathway.  On history, physical and laboratory 
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examination, IPF patients often demonstrate features of chronic hypoxia including 
shortness of breath, reduced diffusion capacity of the lung and 6 minute walk distance 
(6MWD), and decreased partial pressure of oxygen in arterial blood(2, 81). Increased 
immunohistochemical staining for hypoxia inducible factor 1 (HIF1A) on histological 
evaluation of lungs from IPF patients also supports the presence of hypoxia(82). 
Similarly, animal models of bleomycin-induced chronic pulmonary fibrosis show 
decreased arterial oxygen saturation and increased HIF1A in the lungs(83).  Hypoxia 
stabilizes the transcription factor HIF1A which binds to hypoxia-response elements 
within the promoters of target genes involved in the growth of new blood vessels, 
programmed cell-death, and glucose metabolism(71). Specifically, HIF1A has been 
shown to regulate expression of the ADORA2B receptor, CD73, and equilibrative 
nucleotide transporters (ENTs) which allow adenosine transport across the cell 
membrane(90, 91). This regulation ultimately leads to elevation of extracellular 
adenosine levels and enhancement of ADORA2B signaling.  
 
Experimental Rationale  
Although hypoxic conditions are present in IPF and animal models of 
pulmonary fibrosis, the role of hypoxia as a direct modulator of macrophage 
phenotype remains to be understood. Additionally, factors which regulate adenosine 
receptor expression on AAMs and their role in IPF are unknown. An understanding of 
AAMs and previous work demonstrating a pro-fibrotic role for ADORA2B receptor led 
to hypothesis that both hypoxia through HIF1A and alveolar macrophage 
differentiation contribute to the progression of pulmonary fibrosis through up-
regulation of ADORA2B(55, 56). To address this, I examined lung tissues from 
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patients with and without IPF along with luciferase reporter mice during the 
progression of pulmonary fibrosis to show activation and stabilization of HIF1A in 
alternatively activated macrophages. Next, to understand the role of HIF1A in 
regulating ADORA2B expression and the development of pulmonary fibrosis, we 
inhibited HIF1A pharmacologically in late stages of disease in a mouse model and 
observed attenuated pulmonary fibrosis in association with reductions in ADORA2B 
and AAM expression and improved respiratory function. Confirming these in vivo 
findings, in vitro studies in BMDMs support a role for ADORA2B in mediating 
differentiation of macrophages into AAMs, and further demonstrate that antagonism 
or silencing of HIF1Aleads to reductions in ADORA2B expression and ADORA2B-
mediated pro-fibrotic mediator production. These studies shed light on the importance 
of HIF1A in altering the hypoxic adenosine response in pulmonary fibrosis and 
presents a novel means to halting the progression of IPF.  
 
RESULTS 
AAMs show HIF1A stabilization in patients with IPF 
To characterize ADORA2B expression in IPF, whole lung lysate from patients 
with and without IPF was isolated for mRNA and protein analysis. Both ADORA2B 
transcript levels and protein expression were increased in patients with IPF as 
compared to normal controls along with increased HIF1A protein expression (Figure 
4.1A, B). Co-immunofluorescence for the AAM marker, CD206, DAPI nuclear signal, 
and HIF1A were carried out in human lung sections from patients with and without IPF 
to demonstrate HIF1A stabilization. CD206+ macrophages in patients with IPF show 
nuclear localization, or co-localization of DAPI signal and HIF1A, suggesting HIF1A 
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stabilization in comparison to normal lungs (Figure 4.1C). These findings support 
previous work that patients with IPF show evidence of tissue hypoxemia, leading to 
stabilization of HIF1A, and further highlight the importance of alternatively activated 
macrophages as the key effector cell type involved in activation and stabilization 
HIF1A-mediated pathways.  
 
BLM exposure yields AAMs which exhibit HIF1A stabilization  
After demonstrating HIF1A stabilization in AAM’s from patients with IPF, we 
next examined HIF1A stabilization in an experimental model of lung fibrosis using 
intraperitoneal bleomycin exposure(113). HIF1A luciferase (Hif1::LUC) reporter mice 
were injected with bleomycin intra-peritoneally over a four week period to assess 
HIF1A stabilization and localization in vivo. Luciferase activity, as measured by 
relative Firefly-luciferase to Renilla-luciferase activity, was increased in whole lung 
lysate and bronchoalveolar lavage fluid (BALF) from Hif1::LUC reporter mice after 
33-day bleomycin-treatment as compared to PBS treatment (Figure 4.2A, B). Cellular 
differential of BALF cells demonstrate monocytes and macrophages were the 
predominant cell-type which exhibited statistically significant increases in luciferase 
activity after bleomycin treatment (Figure 4.2C).   
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Figure 4.1 CD206+ macrophages exhibit HIF1A stabilization in idiopathic 
pulmonary fibrosis. (A) ADORA2B mRNA expression in whole lung lysate from 
patients without (n=5) and with IPF (n=10). ADORA2B expression was assessed 
using real-time PCR. Data presented as %18s rRNA. (B) Immunoblot for ADORA2B, 
HIF1A, and -actin in whole lung lysate from patients without (n=3) and with IPF (n=9).  
(C) Immunofluorescence for HIF1A (red), CD206 (green), and DAPI (blue) from lung 
sections of human patients with and without IPF. (White arrow: CD206+ cells that 
localize red HIF1A signal in the nucleus with DAPI blue-signal, appear to have purple 
nuclei). Results are presented as mean ± SEM. *p < 0.05, Normal healthy lungs vs 
IPF patients). Scale bar: 25μm (40x). 
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To better understand localization of HIF1A stabilization after bleomycin 
exposure, immunofluorescence for Firefly-luciferase, CD206, and DAPI were carried 
out in lung sections and bronchoalveolar lavage cells. Bleomycin exposure yields 
increased Firefly-luciferase expression, or HIF1A stabilization, in CD206+ AAMs in 
whole lung sections and BALF cells as evidenced by greater intensity yellow signal 
due to co-localization of red Firefly-luciferase and green CD206 signal in comparison 
to Hif1::LUC mice treated with PBS (Figure 4.3A, B). These findings support a role 
for hypoxia-dependent HIF1A stabilization in AAMs in mediating fibrosis in a 
bleomycin-induced mouse model of pulmonary fibrosis.  
 
 
Figure 4.2. Macrophages exhibit HIF1A stabilization in pulmonary fibrosis. 
Luciferase activity as measured by relative Firefly-luciferase to Renilla-luciferase 
activity in whole lung lysate (A) and bronchoalveolar lavage cells (B) of Hif1::LUC 
reporter mice after treatment with PBS (n = 2) or BLM (n = 4) for 33 days. (C) Cellular 
differential in bronchoalveolar lavage fluid (BALF) from Hif1::LUC reporter mice after 
exposure to BLM or PBS for 33 days. Results are presented as mean ± SEM, n = 2-
4. **0.001 < p < 0.01, and *p < 0.05, PBS vs BLM treatment. 
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Figure 4.3. CD206+ macrophages exhibit HIF1A stabilization in pulmonary 
fibrosis after BLM exposure.  Immunofluorescence for Firefly-luciferase (red), 
CD206 (green), and DAPI (blue) in (A) formalin-fixed paraffin-embedded (FFPE) lung 
sections and (B) bronchoalveolar lavage cells in Hif1::LUC reporter mice after 
treatment with PBS or BLM for 33 days. Scale bar: 25μm (40x). 
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A HIF1A inhibitor attenuates pulmonary fibrosis in association with improved 
arterial oxygen saturation  
Our results suggest bleomycin exposure in a mouse model of lung fibrosis and 
in patients with IPF have increased expression and stabilization of the transcription 
factor, HIF1Ain AAM’s and may mediate the development of lung fibrosis through 
activation of hypoxia-responsive genes. These findings in concert with previous 
studies suggesting a role for hypoxia-induced HIF1A in pulmonary fibrosis led us to 
investigate whether pharmacologic inhibition of HIF1A would attenuate pulmonary 
fibrosis(88, 121). C57BL/6 mice were exposed to intra-peritoneal bleomycin and a 
subset were treated with the HIF1A inhibitor, 17-DMAG, beginning on day 20, a time 
point where lung fibrosis is already evident(56). 33 days after bleomycin or PBS 
exposure, whole lung lysate and lung sections were isolated to assess markers of 
fibrosis. HIF1A protein expression in whole lung lysate was reduced in mice treated 
with bleomycin and 17-DMAG as compared to bleomycin alone demonstrating the 
efficacy of the pharmacologic antagonist in HIF1Aknockdown (Figure 4.4A). Collagen 
1A1 transcript levels and Collagen 1 protein expression were increased in C57BL/6 
mice after bleomycin treatment as compared to PBS but reduced in the presence of 
combined bleomycin and 17-DMAG treatment (Figure 4.4B, C, D). Similarly, another 
marker of fibrosis, fibronectin protein expression, was increased in the cohort exposed 
to bleomycin as compared to PBS but decreased with bleomycin and 17-DMAG 
treatment (Figure 4.4E, F).   Immunofluorescence for -smooth muscle actin (SMA) 
was next carried out to identify myofibroblasts in lung sections after bleomycin 
exposure. Myofibroblasts were increased in fibrotic lesions of the lung in mice after  
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Figure 4.4.  HIF1A inhibition attenuates fibrotic markers on day 33 after BLM 
treatment. Immunoblot for (A) HIF1A, (C) Collagen, and (E) Fibronectin and (A,C,E) 
-actin in whole lung lysate from in C57BL/6 mice after 33-day i.p. PBS or Bleomycin 
treatment with vehicle or 25mg/kg 17-DMAG. (B) Collagen 1a1 mRNA expression in 
whole lung lysate and densitometry analysis from immunoblots for (D) collagen and 
(F) fibronectin from C57BL/6 mice after treatment with PBS or BLM ± 17-DMAG. (G) 
Immunofluorescence for -smooth muscle actin staining from formalin-fixed paraffin-
embedded (FFPE) lung sections from C57BL/6 mice after PBS or BLM ± 17-DMAG 
treatment. Results are presented as mean ± SEM, n = 5-7. p < 0.001 PBS-Veh vs 
Bleomycin-veh, ##0.001 < p < 0.01 and #p < 0.05, C57BL/6 Bleomycin-Veh vs C57BL/6 
Bleomycin + 17-DMAG. Collagen 1a1 mRNA expression assessed using real-time 
PCR. Data presented as % 18s rRNA. Images are representative of n ≥ 4 animals 
from each group. Scale bar: 100μm (10x). 
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bleomycin treatment which was attenuated after 17-DMAG treatment of bleomycin-
treated mice (Figure 4.4G). Masson’s Trichrome collagen staining in whole lung 
sections was reduced in mice after bleomycin and 17-DMAG exposure as compared 
to bleomycin treatment alone; these histological findings were quantified over multiple 
lung sections by Ashcroft scores (Figure 4.5A, B). Collagen levels in bronchoalveolar 
lavage fluid as measured by Sircol assay were also reduced in bleomycin-exposed 
mice after 17-DMAG treatment in association with improved arterial oxygen saturation 
as compared to bleomycin treatment alone (Figure 4.5C, D). These findings reveal 
treatment with 17-DMAG, an antagonist to HIF1A, during later stages of disease (day 
20 onwards) in a bleomycin-induced model of pulmonary fibrosis can attenuate lung 
fibrosis, thereby suggesting a role for HIF1A antagonists in treatment of pulmonary 
fibrosis.  
 
HIF1A inhibition attenuates ADORA2B expression and the number of AAMs 
Mice treated with intra-peritoneal bleomycin over 33 days showed increased 
total, macrophage, lymphocyte, and neutrophil cell counts for which 17-DMAG 
treatment led to statistically significant reductions in total and macrophage cell counts; 
lymphocytic cells also appeared to be reduced with bleomycin and 17-DMAG  
treatment although not statistically significant (Figure 5A, B, C, and D).To elucidate 
these changes in macrophage cell count and type, we next evaluated whole lung 
lysate and lung sections for CD206 expression, a marker of AAMs. CD206 protein 
expression was increased with bleomycin exposure yet reduced with 17-DMAG co-
treatment (Figure 4.7A, B).  
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Figure 4.5. HIF1A inhibition attenuates development of pulmonary fibrosis after 
BLM treatment. (A) Masson’s Trichrome collagen staining in whole lung sections with 
quantitative, fibrotic histologic scores as given by (B) Ashcroft scores in C57BL/6 mice 
after 33-day i.p. PBS or Bleomycin treatment with vehicle or 25mg/kg 17-DMAG. (C) 
Sircol Collagen assay in BALF and (D) Arterial oxygen saturation in C57BL/6 mice 
after PBS or BLM treatment ± 17-DMAG. Results are presented as mean ± SEM, n = 
5-7. ****p < 0.001 PBS-Veh vs Bleomycin-veh, ####p < 0.001, ##0.001 < p < 0.01, and 
#p < 0.05, ANOVA comparison between C57BL/6 Bleomycin-Veh vs C57BL/6 
Bleomycin + 17-DMAG. Images are representative of n ≥ 4 animals from each group. 
Scale bar: 200μm (4x). 
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Figure 4.6. Cellular infiltration after 17-DMAG treatment in a BLM-induced 
pulmonary fibrosis model. (A) Total cell counts, (B) macrophages, (C) lymphocytes, 
and (D) neutrophils present in bronchoalveolar lavage fluid (BALF) from C57BL/6 mice 
after 33-day i.p. PBS or Bleomycin treatment with vehicle or 25mg/kg 17-DMAG. 
Results are presented as mean ± SEM, n = 5-7. ****p < 0.001 and **0.001 < p < 0.01 
PBS-Veh vs Bleomycin-veh, ####p < 0.001 C57BL/6 Bleomycin-Veh vs C57BL/6 
Bleomycin + 17-DMAG. 
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Immunostaining of lung sections for CD206 and semi-quantification of CD206+ 
macrophages showed increased AAM in bleomycin-treated mice as compared to mice 
treated with bleomycin and 17-DMAG (Figure 4.7C, D).  Previously, we demonstrated 
a role for ADORA2B expression in myeloid-cells mediating pulmonary fibrosis through 
up-regulation of pro-fibrotic AAMs and subsequent production of pro-fibrotic mediators 
including IL-6(113). To assess the role of HIF1A in mediating ADORA2B expression 
and subsequent pulmonary fibrosis, ADORA2B transcripts were measured in whole 
lung lysate and BALF cells after bleomycin and 17-DMAG treatment. Results revealed 
increases in ADORA2B transcript in whole lung lysate and BALF cells which were 
significantly reduced after treatment with 17-DMAG among BALF cells (Figure 4.7E, 
F), shown earlier to be predominantly macrophages. These findings demonstrate 17-
DMAG treatment attenuates AAMs and ADORA2B expression in lungs of mice after 
bleomycin exposure.  
 
Inhibition of HIF1A in bone marrow-derived macrophages lowers ADORA2B and 
Arginase-1 expression  
In vivo inhibition of HIF1A after bleomycin exposure demonstrated reduced 
pulmonary fibrosis consistent with evidence of decreased ADORA2B and AAM 
expression and improved arterial oxygen saturation. Next, an in-vitro system of bone 
marrow derived macrophages (BMDMs) was utilized to understand the role of hypoxia 
through HIF1A in regulating ADORA2B expression and macrophage differentiation 
into the AAM subtype. BMDMs cultured in the presence of Th2 cytokines, Interleukin-
4 (IL-4) and Interleukin-13 (IL-13), as previously described, and exposure to hypoxia 
(2% O2) for 6 and 12 hours led to robust increases in AAM marker, Arginase-1 
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expression, in comparison to BMDMs treated with IL-4 and IL-13 alone (Figure 4.8A, 
B).   
 
Figure 4.7. HIF1A inhibition reduces ADORA2B expression in BALF cells and 
subsequent markers of AAMs. (A) Immunoblot for AAM marker, CD206, and β-actin 
in whole lung lysate from C57BL/6 mice after 33-day i.p. PBS or BLM treatment with 
vehicle or 25mg/kg 17-DMAG. (B) Densitometry analysis for CD206 immunoblot in 
C57BL/6 mice after BLM 33 day treatment with 17-DMAG. (C) Immunohistochemistry 
for CD206 in FFPE lung sections from C57BL/6 mice after PBS or BLM treatment with 
or without 17-DMAG. Positive staining for CD206 is red/pink; sections were 
counterstained with Gill’s hematoxylin. Black arrows represent macrophages positive 
for CD206. Scale bar: 200 m (40x). (D) Quantification of CD206+ macrophages 
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identified morphologically from CD206-stained lung sections from C57BL/6 mice with 
PBS or BLM ± 17-DMAG treatment. (E) ADORA2B mRNA expression in whole lung 
lysate and (F) BALF cells. ADORA2B (D) expression assessed using real-time PCR. 
Data presented as %18s rRNA. (*p≤0.05 PBS-Veh vs Bleomycin-veh, #p≤0.05 
C57BL/6 Bleomycin-Veh vs C57BL/6 Bleomycin + 17-DMAG). 
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Figure 4.8. Hypoxia exposure yields robust increases in AAMs and regulates 
ADORA2B and AAM marker expression in vitro through HIF1A.  Bone marrow 
derived macrophages from C57Bl6 mice were treated with 10ng/mL IL-4 and 10ng/mL 
IL-13 for 72 hours and then incubated in 2% O2 hypoxia for 6 (A) or 12 (A-I) hours in 
the presence of (D,E) 100M CoCl2 or 3M 17-DMAG, and (F-H) control siRNA and 
siRNA against HIF1A. Immunoblot for HIF1A (E, F), (F) AAM marker, CD206, 
ADORA2B, and -actin after (E) CoCl2 or 17-DMAG and (F) control siRNA and siRNA 
against HIF1A in BMDMs after 72 hour Th2 cytokine and 12 hour hypoxia treatment . 
Arginase-1 (A,B,G) and ADORA2B (C, D,H) expression was assessed using real-time 
PCR. Data presented as %-actin. 
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Similarly, ADORA2B expression was robustly increased in the presence of 
combined IL-4/IL-13 and hypoxia treatment as compared to either IL-4/IL-13 or 
hypoxia exposure alone (Figure 4.8C). To test the hypothesis that hypoxia through 
HIF1A is largely responsible for mediating ADORA2B expression on Th2-treated 
BMDMs, a HIF1A stabilizer, CoCl2, was used in addition to 17-DMAG. Treatment with 
CoCl2 led to increased ADORA2B expression which was reversed in the presence of 
17-DMAG in association with reductions in HIF1A protein expression (Figure 4.8D, E). 
Signal Transduction and Activator of Transcription-6 (STAT-6) is known to be 
the predominant signaling pathway through which IL-4 and IL-13 activate 
differentiation of macrophages into AAMs (97, 99, 100, 122). To understand the role 
for STAT-6 as a regulator of ADORA2B expression on AAMs in culture, BMDMs were 
exposed to IL-4/IL-13 and hypoxia in the presence of a STAT-6 inhibitor, AS 1517499 
(100nM)(101). STAT-6 inhibition of Arginase-1 expressing BMDMs led to no 
significant difference in ADORA2B expression (Figure 4.9A,B).   
 
Figure 4.9. ADORA2B expression on AAMs is STAT6-independent. Bone marrow 
derived macrophages from C57Bl6 mice were treated with 10ng/mL IL-4 and 10ng/mL 
IL-13 for 72 hours and then incubated in 2% O2 hypoxia for 12 hours in the presence 
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of 200nm AS1517599, a STAT-6 inhibitor. Arginase-1 (A) and ADORA2B (B) 
expression was assessed using real-time PCR. Data presented as %-actin. 
Confirming the results of HIF1A stabilization and inhibition from above with 
CoCl2 and 17-DMAG, genetic knockdown of HIF1Athrough siRNA silencing in IL-4/IL-
13-treated BMDMs exposed to hypoxia led to reduced HIF1A protein expression and 
subsequent ADORA2B mRNA and protein expression in conjunction with reduced 
AAMs, as evidenced by decreased CD206 protein and Arginase-1 mRNA expression 
(Figure 4.8G, H, and I). Together, these data highlight the role of hypoxia through 
HIF1A as the predominant driver of ADORA2B expression on Arginase-1 expressing 
BMDMs.  
 
HIF1A antagonism in lung macrophages after bleomycin exposure reduces 
ADORA2B and pro-fibrotic mediator expression  
To validate the findings above in macrophages after bleomycin-exposure, lung 
macrophages were isolated from whole lung after intra-peritoneal bleomycin treatment 
and treated with CoCl2 and 17-DMAG. Treatment with HIF1A stabilizer, CoCl2, led to 
increases in ADORA2B, IL-6, and CXCL1 expression which were reduced in the 
presence of the HIF1A inhibitor, 17-DMAG (Figure 4.10A, B, and C). These data 
suggest a role for antagonism of HIF1A in treatment of pulmonary fibrosis by 
mediating reductions in ADORA2B expression on AAMs, differentiation of 
macrophages further into AAMs, and subsequent pro-fibrotic mediator production.  
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Figure 4.10. Antagonism of HIF1A reduces ADORA2B expression and 
subsequent pro-fibrotic mediator production in lung macrophages after BLM 
treatment. Macrophages were isolated from whole lung lysate of C57BL/6 mice after 
i.p. bleomycin treatment for 33 days. Isolated macrophages were then treated with 
100M CoCl2 or 3M 17-DMAG for 12 hours. (A) ADORA2B, (B) Interleukin-6, and 
(C) CXCL1 mRNA expression was assessed using real-time PCR. Results are 
presented as mean ± SEM, n = 2-4. Data presented as %-actin. *p < 0.05 CoCl2 
treatment vs no CoCl2, ## 0.001 < p < 0.01 and #p < 0.05 CoCl2 vs CoCl2 + 17-DMAG. 
 
DISCUSSION 
Previous work has demonstrated a role for ADORA2B-mediated pro-fibrotic 
effects in pulmonary fibrosis(56). Although ADORA2B is expressed throughout the 
lung, Zhou et al. demonstrated that ADORA2B-expressing, CD206+ macrophages, a 
marker for AAMs, was elevated in patients with IPF and animals models of bleomycin-
induced chronic lung disease(55).  AAM’s have been implicated in many diseases as 
a key effector cell type involved in remodeling including asthma and systemic 
scleroderma(103, 123). Although, it is known that patients with IPF demonstrate 
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clinical features of hypoxia and hypoxemia, the role for hypoxia as a modulator of 
adenosine signaling and macrophage differentiation in pulmonary fibrosis remains 
unknown. Our studies demonstrated the transcription factor HIF1A as a key hypoxia-
dependent mediator which is stabilized in IPF patients and mice after bleomycin 
exposure. We illustrated a role for HIF1Ain mediating ADORA2B expression and 
subsequent AAM differentiation and pro-fibrotic mediator production. Inhibition of 
HIF1A in vivo attenuated pulmonary fibrosis in association with reduced ADORA2B 
and AAM expression in association with improved arterial oxygen saturation. These 
findings were validated in lung macrophages from bleomycin-exposed mice and a 
robust in vitro bone marrow-derived macrophage system illustrating the involvement 
of hypoxia through HIF1A being a key regulator of ADORA2B expression on 
macrophages, their differentiation into the pro-fibrotic AAM subtype, and production 
of pro-fibrotic mediators including IL-6 and CXCL1. Our data suggest a clinically 
significant use for HIF1A antagonists in targeting the hypoxic adenosine response as 
a treatment for patients with IPF.   
 Hypoxia is known to regulate elements of the adenosine signaling pathway 
including down-regulation of CD73 and ENTs leading to increase concentrations of 
adenosine in the extracellular space(90, 91). The presence of a hypoxia response 
element (HRE) on the promoter of ADORA2B supports the notion that hypoxia through 
HIF1A will lead to up-regulation of ADORA2B as described previously(88, 90). HIF1A 
transcript and protein expression have been found to be elevated in patients with IPF 
and mouse models of bleomycin-induced lung fibrosis(82, 83). A key finding of this 
work however emphasizes the nuclear localization and stabilization of HIF1A 
specifically in CD206+ macrophages for the first time in patients with IPF and a mouse 
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model after bleomycin exposure. These data further support a key role for AAM’s as 
a cell type mediating release of pro-fibrotic mediators including IL-6, which further 
increase extracellular matrix production and the fibrotic phenotype through IL-6 
mediated trans-signaling on fibroblasts in the lung(124). Further studies in 
macrophages from bronchoalveolar lavage fluid from patients with and without IPF is 
needed to support whole lung findings of HIF1A stabilization on histology. Results 
from bleomycin treatment of Hif1::LUC reporter mice support the importance of other 
cell-types in stabilization of HIF1A including hypoxia-mediated induction of 
deoxycytidine kinase which has been implicated in alveolar epithelial cell 
proliferation(84). Further work is needed to delineate the contribution and interplay of 
these various cell types in the development and progression of pulmonary fibrosis.  
 A major finding of this work was the demonstration of a role for HIF1A inhibition 
in attenuating pulmonary fibrosis in mice after bleomycin exposure. We previously 
showed a role for the presence of ADORA2B on myeloid cells in mediating the 
development of pulmonary fibrosis through regulation of AAMs(113). This finding led 
us to investigate the hypoxia pathways upstream of ADORA2B which may be involved 
and their role in regulating ADORA2B expression and macrophage differentiation. We 
showed that treatment with a HIF1A antagonist, 17-DMAG, decreases pulmonary 
fibrosis as evident by reductions in key extracellular matrix proteins including collagen 
I and fibronectin. This reduction in fibrosis was associated with improvements in 
arterial oxygen saturation and significant reductions in ADORA2B transcript levels in 
bronchoalveolar lavage cells, known to be comprised significantly of macrophages. 
To further elucidate the role of HIF1A-mediated ADORA2B expression on 
macrophages, we assessed expression of an AAM marker, CD206, and found 
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significant reductions in CD206+ macrophages after 17-DMAG treatment in whole 
lung lysate and histology sections. These findings suggest a critical role for 
antagonizing hypoxia-dependent HIF1A stabilization through treatment with an 
antagonist in late stages of disease as a potential therapeutic for patients with IPF. 
These studies are limited however in that 17-DMAG was delivered systemically 
through intraperitoneal injection versus localized delivery to the lung; however, 
western blot analysis of HIF1A in whole lung lysate suggest that despite systemic 
delivery of the drug, we were still able to achieve significant decreases in HIF1A 
expression. Recent work suggesting a protective role for HIF1A in epithelial cells in 
acute lung injury could lead to further experiments investigating the role of HIF1A 
antagonism or genetic knockdown in early stages of disease as well(89).  
Patients with IPF are known to have a Th2 cytokine rich environment as evident 
through increased presence of IL-4 and IL-13 in bronchoalveolar lavage fluid from 
patient samples and immunohistochemical staining(125-128). Although patients with 
IPF are known to be hypoxic, the contribution of hypoxia to Th2 cytokine treatment on 
ADORA2B expression on macrophages and subsequent differentiation and pro-
fibrotic mediator production is unknown. To address this knowledge gap, bone marrow 
derived macrophages were utilized and we observed a robust increase in ADORA2B 
expression after hypoxia and Th2 cytokine treatment; however, we further illustrated 
that this increase in ADORA2B expression on macrophages is predominantly 
mediated by hypoxia through HIF1A as demonstrated by reductions in ADORA2B 
expression with addition of HIF1A antagonist treatment to hypoxia as compared to no 
significant change in ADORA2B expression with addition of a STAT-6 inhibitor. Similar 
results were observed with reductions in ADORA2B expression, Arginase-1 and 
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CD206 expression with genetic silencing of HIF1A. These findings were validated in 
another macrophage system, lung macrophages isolated from mice after bleomycin 
treatment, wherein co-treatment of 17-DMAG with CoCl2, HIF1A stabilizer, led to 
reductions in ADORA2B, IL-6, and CXCL1. These data support another major finding 
from this study that hypoxia through HIF1A regulates ADORA2B expression on 
macrophages, differentiation of macrophages into AAMs, along with pro-fibrotic 
mediator production. Antagonism of HIF1A in BMDMs led to decreases in pro-fibrotic 
mediator production revealing new targets for halting the progression of pulmonary 
fibrosis in patients with IPF. Future work will include elucidating the impact of hypoxia-
independent pathways, whether stretch-induced or metabolite-mediated, on upstream 
HIF1A stabilization. The HIF2A subunit has also gained attention as it has been shown 
to play a role in the development of pulmonary hypertension and fibrosis in genetically-
modified mice(121). Recent work by Cowburn et al. suggest the development of 
pulmonary hypertension may be due to hypoxia-induced HIF2A stabilization which 
increases arginase expression thereby disrupting protective effects of nitric oxide on 
the pulmonary vasculature(129). As such, further work may include investigating the 
contribution of HIF2A in the development of pulmonary fibrosis and associated 
pulmonary hypertension after bleomycin exposure. It may also be insightful to 
elucidate the possibly differing role of adenosine receptor expression, role of HIF1A 
stabilization, and differentiation on alveolar, interstitial, or recruited macrophages in 
pulmonary fibrosis alongside validation in macrophages isolated from patients with 
and without IPF.  
In Chapter 3 of the dissertation, we reveal a role for the presence of ADORA2B 
on myeloid cells in promoting their differentiation into the AAM subtype, production of 
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pro-fibrotic mediators, and ultimately, the development of pulmonary fibrosis after 
bleomycin exposure. The contribution of hypoxia as a regulator of ADORA2B 
expression on AAMs and development of pulmonary fibrosis is explored in this 
chapter. I found that antagonism or genetic silencing of HIF1A can attenuate pro-
fibrotic mediator production and pulmonary fibrosis in bone marrow derived 
macrophages (BMDMs) and in vivo models of bleomycin-induced pulmonary fibrosis. 
In the following chapter, I will examine the effect of myeloid-specific HIF1A deletion 
on the development and progression of pulmonary fibrosis and a pivotal role which 
HIF1A plays in acute stages of disease.  
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CHAPTER FIVE 
MYELOID-SPECIFIC HIF1A DELETION EXACERBATES ACUTE LUNG INJURY 
CONTRIBUTING TO PULMONARY FIBROSIS 
 
INTRODUCTION 
Note: This chapter is based upon: Philip K, Mills T, Davies J, Chen NY, Karmouty-
Quintana H, Hernandez A, Luo F, Molina JG, Eltzschig HK, and Blackburn MR. 
Myeloid-specific HIF1A deletion exacerbates acute lung injury. In Preparation.  
 
In the previous chapter, I demonstrate a role for ADORA2B on myeloid cells in 
mediating macrophage differentiation and subsequent pro-fibrotic mediator production 
in an in vivo bleomycin-induced model of lung fibrosis and bone marrow derived 
macrophages(113). Chapter 4 then explores how hypoxia through HIF1A acts as a 
regulator of ADORA2B expression on AAMs and HIF1A inhibition in late stages of 
disease can be used to attenuate the development of pulmonary fibrosis in an in vivo 
mouse model. Additionally, bone marrow derived macrophages were used to decipher 
between the roles of Th2 cytokine signaling through STAT-6 and hypoxia through 
HIF1A in culture in mediating ADORA2B expression, AAM differentiation, and 
subsequent interleukin-6 production. Although these studies provide evidence for a 
therapeutic role of HIF1A or ADORA2B inhibition in the development and progression 
of pulmonary fibrosis, the role of HIF1A on myeloid cells in altering adenosine 
signaling and the inflammatory mileau in early stages of lung injury remains to be 
understood and will be discussed in this chapter.  
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HIF1A in Lung Disease 
Numerous pulmonary diseases are known to result in hypoxia and more 
attention has been drawn to the interplay between hypoxia and inflammation(51). 
Systemic or organ-specific hypoxia has been shown to promote an inflammatory 
response including immunocyte recruitment, increased endothelial cell permeability 
and resulting vascular leakage, and the activation of proinflammatory signaling 
pathways, cytokines, and chemokines(130). Inflammation itself, including increases 
in mediators such as nitric oxide, can contribute to the development of hypoxia and 
subsequent HIF1A expression, ultimately disrupting epithelial cell wound repair(72, 
131). Although multiple mechanisms exist to activate HIF, hypoxia-dependent PHD 
inhibition and subsequent HIF1A stabilization is the focus of this chapter as HIF1A is 
known to be stabilized in patients with IPF, mouse models of bleomycin-induced lung 
injury, and we have demonstrated in the preceding chapters its activation in lung 
macrophages from patients with IPF and animal models of disease (75, 82, 83)  
Recent work by Eckle et al. observed exacerbations in pulmonary edema and 
inflammation after alveolar-epithelial cell specific HIF1A knockout mice were exposed 
to ventilator-induced lung injury suggesting a protective, anti-inflammatory role for 
HIF1A (89). They later showed that stabilization of HIF1A in this cyclic mechanical-
stretch induced model of lung injury lead to upregulation of ADORA2B in epithelial 
cells and subsequent anti-inflammatory effects in agreement with previous work from 
our laboratory revealing an anti-inflammatory, protective role for ADORA2B itself in 
acute lung injury(56, 88). In support of a pro-fibrotic role for HIF1A in this same cell 
type, alveolar epithelial cells, our lab has shown that hypoxia-mediated HIF1A 
stabilization can also induce deoxycytidine kinase expression in alveolar epithelial 
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cells contributing to their proliferation and the development of lung fibrosis in a model 
of bleomycin-induced chronic lung disease (84). Myeloid-specific HIF1A knockout 
mice showed decreased airway hyperresponsiveness and recruitment of asthmatic 
inflammatory mediators, eosinophils, when exposed to ovalbumin supporting 
however a protective anti-inflammatory role of HIF1A in acute lung injury in another 
cell type (132).  Together these studies demonstrate a tissue-protective, anti-
inflammatory role for HIF1A in acute stages of lung injury in differing cell types. 
However, the role of HIF1A in myeloid cells in acute stages of a bleomycin-induced 
lung injury model and its subsequent effects on late stages of disease remain to be 
understood and will be the focus of this chapter.  
 
Experimental Rationale  
      We have previously demonstrated differing roles for ADORA2B depending on the 
stage of disease. In an intra-tracheal model of bleomycin-induced acute lung injury, 
ADORA2B-/- mice are found to exhibit increases in pulmonary edema and acute 
inflammatory markers revealing a protective and anti-inflammatory role for ADORA2B 
in acute lung injury(54, 56). ADORA2B-/- mice however exposed to an intra-peritoneal 
model of bleomycin-induced chronic lung disease show reductions in fibrotic markers 
such as collagen and fibronectin, attenuated fibrosis and profibrotic mediators 
including macrophages expressing interleukin-6, and clinical improvement 
demonstrating a detrimental role for ADORA2B in chronic lung disease(56).  
The previous chapter directly illustrates how antagonism of HIF1A can lead to 
reductions in ADORA2B, disrupted macrophage differentiation into the profibrotic 
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AAM subtype, and subsequently attenuate lung fibrosis; ultimately, revealing a novel 
therapeutic target for patients with IPF. To investigate the impact of HIF1A on lung 
disease in acute stages of injury, a myeloid-specific HIF1A knockout mice was 
generated and exposed to saline or bleomycin over the 33 day time course. Samples 
were collected at initial stages of injury, day 3, 7 and 14, in addition to late stages of 
disease, 21 and 33 to evaluate the role HIF1A may play as a regulator in mediating 
the differing roles of ADORA2B on myeloid cells in acute versus chronic lung injury.  
 
RESULTS 
Myeloid-specific HIF1A deletion alters temporal changes in cellular 
inflammation and increases neutrophil infiltration after BLM exposure 
 HIF1Af/fLysMCre and LysMCre mice were treated with intra-peritoneal bleomycin 
over 33 days, sacrificed, and samples collected at varying time points. Overall, mice 
lacking ADORA2B on myeloid cells showed similar trends but still a significant 
reduction in total cell count in bronchoalveolar lavage fluid when compared to control 
mice after bleomycin treatment by day 20 (Figure 5.1A). Upon closer evaluation of the 
cellular differential in BALF, it is evident that HIF1Af/fLysMCre treated with bleomycin 
show significant increases in acute inflammatory mediators, including neutrophils by 
day 7 and lymphocytes by day 14 as compared to LysMCre mice after bleomycin 
exposure (Figure 5.1B,C, 5.2A). Macrophage cell counts followed an increase by day 
14 and 20 after bleomycin treatment for both HIF1Af/fLysMCre and LysMCre mice 
although they were significantly reduced in mice lacking ADORA2B on myeloid cells 
(Figure 5.1D). To further distinguish these changes in neutrophil cell count by day 7, 
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lung sections were stained for Ly.6b expression, a surface marker found on murine 
neutrophils (Figure 5.2B) (133). Semi-quantification of Ly.6b positive cells shows 
increased neutrophils in bleomycin-treated HIF1Af/fLysMCre mice as compared to 
LysMCre mice after bleomycin exposure (Figure 5.2C).  
 
Figure 5.1. Temporal changes in cellular infiltration after BLM exposure. (A) Total 
cell counts, (B) neutrophils, (C) lymphocytes, and (D) macrophages present in 
bronchoalveolar lavage fluid (BALF) from HIF1Af/fLysMCre and LysMCre mice after i.p. 
PBS or Bleomycin treatment for 3, 7, 14, 20, or 33 days. Results are presented as 
mean ± SEM, n = 5-12. ****p < 0.001,  **0.001 < p < 0.01, *p < 0.05, ANOVA comparison 
between LysMCre + PBS and LysMCre + Bleomycin. ####p < 0.001, ##0.001 < p < 0.01, 
and #p < 0.05, ANOVA comparison between LysMCre + Bleomycin and HIF1Af/fLysMCre 
+ Bleomycin.  
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Figure 5.2 BLM exposure in myeloid-specific HIF1A knockout mice increases 
early neutrophil infiltration. (A) Neutrophils cell counts in bronchoalveolar lavage 
fluid (BALF), (B) Immunohistochemistry for Ly.6b in FFPE lung sections, and (C) semi-
quanitification of Ly.6b positive cells identified morphologically in stained sections from 
HIF1Af/fLysMCre and LysMCre mice after i.p. PBS or Bleomycin treatment for 7 days. 
Positive staining for Ly.6b is brown; sections counterstained with methylgreen. Black 
arrows represent Ly.6b positive cells, or neutrophils. Results are presented as mean 
± SEM, n = 5-12. *p < 0.05, ANOVA comparison between LysMCre + PBS and LysMCre 
+ Bleomycin. #p < 0.05, ANOVA comparison between LysMCre + Bleomycin and 
HIF1Af/fLysMCre + Bleomycin. Images are representative of n ≥ 4 animals from each 
group.  
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HIF1A deletion on myeloid cells exacerbates acute lung injury after BLM 
exposure 
 Results above suggest bleomycin exposure in mice lacking HIF1A on myeloid 
cells lead to alterations in acute inflammatory mediators including neutrophils and 
lymphocytes in comparison to control mice after bleomycin treatment. These 
observations lead us to further investigate other markers of acute lung injury. Next, to 
assess loss of the pulmonary barrier function and the development of pulmonary 
edema, we evaluated albumin levels in the BALF on day 7 and found significant 
increases in HIF1Af/fLysMCre mice after bleomycin exposure as compared to control 
mice with bleomycin treatment (Figure 5.3A). To further evaluate chemokines involved 
in neutrophil recruitment in the setting of acute lung injury, we evaluated mRNA levels 
of monocyte chemotactic peptide-1 (MCP-1) and found increases in control 
bleomycin-treated LysMCre mice which were robustly increased after bleomycin 
treatment in mice lacking HIF1A on myeloid cells (Figure 5.3B) (31, 37, 38). Similarly, 
another indicator of acute lung injury, Myeloperoxidase (MPO), a major component of 
neutrophil cytoplasmic granules revealing neutrophil presence, was found to be 
significantly increased in BALF on day 7 after bleomycin exposure in HIF1Af/fLysMCre 
mice (Figure 5.3C)(134). These findings reveal myeloid-specific HIF1A deletion 
followed by acute lung injury through bleomycin exposure will not only increase 
neutrophil count, but contribute to worsening pulmonary edema, greater neutrophil 
recruitment, and ultimately, increased inflammation, thereby suggesting a protective 
role for HIF1A in acute lung injury.  
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Figure 5.3 Deletion of HIF1A on myeloid cells exacerbates ALI markers in BLM-
induced lung fibrosis. (A) Albumin concentration in bronchoalveolar lavage fluid, (B) 
MCP-1 mRNA expression in whole lung lysate, and (C) myeloperoxidase activity in 
bronchoalveolar lavage fluid after bleomycin exposure at day 7 in HIF1Af/fLysMCre and 
LysMCre mice. Results are presented as mean ± SEM, n = 5-12. ###p < 0.001, #p < 
0.05, ANOVA comparison between LysMCre + Bleomycin and HIF1Af/fLysMCre + 
Bleomycin. MCP-1 mRNA expression assessed using real-time PCR. Data presented 
as % 18s rRNA.  
 
HIF1A deletion on myeloid cells increases pulmonary fibrosis in association 
with worsened arterial oxygen saturation 
 Thus far, data reveal an anti-inflammatory role for HIF1A on myeloid cells in 
acute stages of bleomycin exposure as evidenced by increases in acute inflammatory 
mediators, neutrophil recruitment, count, MPO, and loss of barrier function in 
bleomycin-treated myeloid specific HIF1 knockout mice. This worsening of acute lung 
injury due to loss of HIF1A on myeloid cells led us to investigate whether pulmonary 
fibrosis would also be exacerbated as has been shown previously(135).   LysMCre 
control mice and HIF1Af/fLysMCre mice were treated with bleomycin intraperitoneally 
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over 33 days. Assessing fibrotic markers in whole lung lysate on day 33 reveal 
increased fibronectin protein expression and collagen 1a1 transcript levels in mice 
lacking ADORA2B on myeloid cells as compared to bleomycin treatment of control 
mice alone (Figure 5.4 A,B). Immunofluorescence for -smooth muscle actin (SMA), 
a marker of myofibroblasts in lung sections, revealed increased staining after 
bleomycin treatment of control mice as compared to saline which was further 
increased in HIF1Af/fLysMCre mice after bleomycin treatment in association with 
reductions in arterial oxygen saturation (Figure 5.4C,D). Masson’s Trichrome collagen 
staining in whole lung sections was increased in LysMCre mice after bleomycin 
exposure by day 14 and continued to increase by day 21 and 33 (Figure 5.5A).  
HIF1Af/fLysMCre mice exposed to bleomycin shows similar increase in collagen 
staining by day 14 but demonstrated statistically significant increases in collagen 
staining as quantified by Ashcroft histological score by day 33 (Figure 5.5 A,B). 
Together, these data reveal myeloid specific HIF1A deletion in a bleomycin-induced 
model of lung fibrosis will worsen lung fibrosis, as a result of the loss of the protective 
anti-inflammatory effects of HIF1A in acute stages of disease.  
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Figure 5.4 Fibrotic markers are increased on day 33 after BLM exposure in mice 
lacking HIF1A on myeloid cells. Immunoblot for (A) Fibronectin and (B) Collagen 
1a1 mRNA expression in whole lung lysate from HIF1Af/fLysMCre and LysMCre mice 
after i.p. PBS or Bleomycin exposure on day 33. (C) Immunofluorescence for alpha-
smooth muscle actin staining from formalin-fixed paraffin-embedded (FFPE) lung 
sections and (D) Arterial oxygen saturation in HIF1Af/fLysMCre and LysMCre mice after 
33 days of bleomycin treatment. Images are representative of n ≥ 4 animals from each 
group. Scale bar: 100μm (10x).  
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Figure 5.5 Myeloid HIF1A deletion exacerbates the development of pulmonary 
fibrosis after BLM treatment. (A) Masson’s Trichrome collagen staining in whole 
lung sections with quantitative, fibrotic histologic scores as given by (B) Ashcroft 
scores in HIF1Af/fLysMCre and LysMCre mice after i.p. PBS or Bleomycin exposure on 
day 14, 20, and 33. Results are presented as mean ± SEM, n = 5-7. ****p < 0.001 LysMCre + 
PBS vs LysMCre + Bleomycin and ####p < 0.001, ANOVA comparison between LysMCre + 
Bleomycin and HIF1Af/fLysMCre + Bleomycin.  
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Myeloid-specific HIF1A deletion attenuates ADORA2B and AAM expression 
after BLM exposure 
HIF1Af/fLysMCre after bleomycin treatment showed increases in macrophage 
cell count as observed in bleomycin-treated LysMCre however, they were significantly 
reduced compared to treated control mice at day 14 and 21 (Figure 5.1D). To decipher 
these changes in macrophage cell count, whole lung lysate was evaluated for markers 
of AAMs. CD206 protein expression was increased with bleomycin exposure in control 
LysMCre mice as compared to PBS treatment but reduced in those bleomycin-treated 
mice lacking ADORA2B on myeloid cells (Figure 5.6A). In accord with this, transcript 
levels in lung lysate of another AAM marker, Arginase-1, were increased with 
bleomycin exposure and reduced in myeloid-specific HIF1A knockout mouse (Figure 
5.6B). In Chapter 3, I demonstrated that activation of ADORA2B on myeloid cells up-
regulates pro-fibrotic AAMs, profibrotic mediators, and contributes to the development 
of pulmonary fibrosis(113). In chapter 4, HIF1A was found to mediate ADORA2B 
expression on BMDMS and in vivo attenuating lung fibrosis. In agreement with these 
findings, ADORA2B transcript levels were increased after bleomycin exposure in 
control mice yet reduced in bleomycin-treated mice lacking HIF1A on myeloid cells. 
Together, these results demonstrate myeloid-specific HIF1A deletion reduces AAM 
and ADORA2B expression after bleomycin exposure.  
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Figure 5.6. Conditional myeloid-specific HIF1A deletion yields decreased 
ADORA2B and AAM expression after BLM-induced pulmonary fibrosis. (A) 
Immunoblot for CD206 and -actin, (B) Arginase-1, and ADORA2B transcript levels 
(C) in whole lung lysate from HIF1Af/fLysMCre and LysMCre mice exposed to bleomycin 
or PBS 33 days after treatment. Arginase-1 and ADORA2B expression was assessed 
using real-time PCR. Data presented as %18s rRNA.  
 
HIF1A deletion in myeloid cells in bone marrow-derived macrophages lowers 
Arginase-1 and production of pro-fibrotic mediators 
 In vivo bleomycin exposure in myeloid-specific HIF1A conditional knockout 
mice resulted in exacerbated pulmonary inflammation and subseqent increases in 
fibrosis despite reductions in ADORA2B and AAM expression. To confirm the role of 
hypoxia through HIF1A in regulating macrophage differentiation observed in chapter 
4, bone marrow-derived macrophages from HIF1Af/fLysMCre and LysMCre mice were 
cultured in the presence of IL-4 and IL-13 and exposed to hypoxia for 12 hours. 
Treatment of hypoxia and Th2-cytokine treated LysMCre BMDMs with NECA, a pan-
adenosine receptor agonist, resulted in increases in Arginase-1, Interleukin-6, and 
CXCL1 transcript levels which were significantly reduced in BMDMS lacking HIF1A 
(Figure 5.7A,B,C). This suggests HIF1A on myeloid cells is needed for ADORA2B-
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mediated stimulation of macrophage differentiation into AAMs and profibrotic mediator 
production. 
 
 
Figure 5.7. AAM and pro-fibrotic mediator expression is reduced after 
adenosine receptor activation in BMDMS lacking HIF1A. HIF1Af/fLysMCre and 
LysMCre BMDMs were treated with IL-4 and IL-13 for 72 hours, then incubated in 
hypoxia (2% O2) for 12 hours in the presence of 10M NECA. (A) Arginase-1, (B) 
Interleukin-6, and (C) CXCL1 mRNA expression was assessed using real-time PCR. 
Data presented as %-actin.  
 
DISCUSSION 
      HIF1A has received recent attention as a transcription factor which can play a 
protective role in various types of acute lung injury including normoxic ventilator-
induced lung injury and ovalbumin challenge models of airway hyperresponsiveness 
and asthma(89, 132). These findings however were specific to other cell types in the 
lung including alveolar epithelial cells and eosinophils. In Chapter 4, we demonstrated 
stabilization of HIF1A in macrophages from IPF patients and bleomycin-induced 
models of lung injury; in this chapter however, I utilized a myeloid-specific HIF1A 
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knockout mice to understand the role HIF1A plays in acute and chronic stages of a 
bleomycin-induced model of lung injury.  
The results above demonstrate myeloid-specific HIF1A deletion followed by 
bleomycin exposure leads to worsening of pulmonary inflammation in acute stages 
and subsequent pulmonary fibrosis in association with reductions in arterial oxygen 
saturation. In accord with results of the previous chapter, a role for HIF1A in regulating 
ADORA2B expression, macrophage differentiation, and subsequent profibrotic 
mediator production was illustrated in chronic stages of a bleomycin-induced lung 
disease and BMDMs from conditionally modified mice lacking HIF1A on myeloid cells. 
Moreover, these studies support a role for myeloid-specific HIF1A agonists or 
stabilizers in treating patients with acute lung injury or myeloid-specific HIF1A 
antagonists or inhibitors in patients with chronic lung diseases such as IPF.  
 A mouse model of bleomycin-induced lung injury in acute stages of disease 
reveals a protective role for HIF1A on myeloid cells in reducing inflammation. Mice 
lacking HIF1A in myeloid cells showed exacerbations of acute lung injury including 
increased pulmonary edema, acute inflammatory markers, chemokines, and 
neutrophil recruitment. These data are novel in that they are the first to suggest HIF1A 
in AAMs as a key factor in reducing inflammation and protecting pulmonary barrier 
function in a bleomycin-induced model of lung injury.  Crotty et al. recently showed 
inhibition of HIF1A and myeloid-specific HIF1A knockouts exposed to ovalbumin had 
reductions in airway hyper-responsiveness and eosinophil recruitment, features of 
asthma pathogenesis(132).  Supporting a similar anti-inflammatory role, Eckle et al. 
demonstrate HIF1A stabilization in normoxia under mechanical stretch and ventilator-
induced acute lung injury leads to decreases in pulmonary edema and inflammation 
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associated with maximal carbohydrate metabolism in vivo; these observations were 
exacerbated in alveolar-epithelial cell specific HIF1A knockout mice after VILI, 
localizing this anti-inflammatory role of HIF1A to alveolar epithelial cells(89). As such, 
our findings further support previous work indicating HIF1A plays an anti-inflammatory 
role in myeloid cells in acute lung injury, or bleomycin exposure as demonstrated here. 
Further work includes investigating the contribution of other cell types which exhibit 
HIF1A stabilization in the bleomycin lung injury model. Additionally, evaluating 
conditions that promote HIF1A stabilization in normoxic conditions in myeloid cells 
may be key to preventing inflammation and subsequent fibrosis development in 
patients at risk for the development of IPF or other chronic lung diseases.  
This work supports the consistent finding observed in previous chapters that 
HIF1A drives ADORA2B expression, macrophage differentiation, and pro-fibrotic 
mediator production. Thirty-three day bleomycin exposure in myeloid-specific HIF1A 
knockout mice resulted in decreased CD206 protein, Arginase-1, and ADOR2B 
transcript levels in whole lung lysate. Given the reductions in ADORA2B as regulated 
by HIF1A, one may expect lung fibrosis to be reduced as well based on findings from 
the two previous chapters; however, the resultant increase in fibrosis differs from the 
previous studies in that lung injury due to bleomycin exposure was exacerbated 
acutely secondary to myeloid-specific HIF1A deletion in comparison to myeloid-
specific ADORA2B deletion (Chapter 3) or HIF1A inhibition in late stages of disease 
(Chapter 4). We have previously observed similar increases in inflammation as 
evidenced by lowered adenosine levels and increasing cellular infiltration, pro-
inflammatory mediators including interleukin-1, TNF, which contributed to 
increased lung fibrosis after bleomycin treatment of CD73-/- mice(135). CD73 is known 
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to have a HRE on its promoter and as such it maybe that myeloid-specific HIF1A 
deletion leads to decreased levels of CD73, lowering adenosine levels, and ultimately 
exacerbating injury in the acute phase of a bleomycin-induced model of lung 
injury(92). TGF is another mediator which was found to be elevated in lung 
macrophages after adenosine-dependent lung injury in which increased inflammation 
and subsequent fibrosis was observed in ADA-/- mice which improved with 
antagonism of ADORA2B (136). These elevations in TGF were also observed in 
ADORA2B-/- mice during acute stages of the bleomycin-induced lung injury model 
(56). Further work to evaluate the mechanism by which HIF1A deletion on myeloid 
cells exacerbates acute lung injury includes assessing adenosine levels in 
bronchoalveolar lavage fluid, CD73 and TGF expression in whole lung lysate and 
lung sections, in addition to evaluating pro-inflammatory and pro-fibrotic mediators.  
Moreover, these data demonstrate an anti-inflammatory role for HIF1A on 
myeloid cells in acute lung injury. Mice lacking HIF1A on myeloid cells exhibit 
increased inflammation and pulmonary edema which contributes to increases in 
fibrotic markers including collagen and fibronectin and the development of fibrosis in 
later stages of disease. Chapter 3 and 4 revealed how activation of ADORA2B and 
HIF1A stabilization ultimately mediate macrophage differentiation into AAMs and pro-
fibrotic mediator production. In agreement, this chapter illustrated a decrease in AAM 
and ADORA2B expression in conditional myeloid-specific HIF1A knockouts after 
bleomycin exposure and BMDMS after NECA treatment.  
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CHAPTER SIX 
SUMMARY, FUTURE DIRECTIONS, AND CONCLUSION 
SUMMARY 
IPF is a common, chronic disease which significantly impacts the quality of life of 
millions of individuals worldwide. Median survival after diagnosis is typically 3-5 years 
due to the absence of any curative treatment(1, 128, 137). Previously published work 
from our lab and others have demonstrated a role for adenosine accumulation and 
activation of ADORA2B as a key regulator of fibrosis in vivo and in conjunction with 
human samples of IPF, ADORA2B expression and IL-6 production has been localized 
to alternatively, activated macrophages as a key effector cell-type in this process(50, 
55, 56). The work in this dissertation sought to identify factors which regulated 
expression of ADORA2B on macrophages, elucidate the role ADORA2B in 
macrophage differentiation and development of fibrosis, and assess the impact of 
inhibiting HIF1A in late stages of disease versus myeloid-specifIc HIF1A deletion on 
pulmonary fibrosis.  
 Bleomycin exposure of myeloid-specific ADORA2B knockouts revealed 
reductions in markers of fibrosis including collagen, fibronectin, and myofibroblast 
expression in association with improvements in arterial oxygen saturation. Upon 
further inspection of macrophage cell counts and type, we found that the attenuation 
of fibrosis was also associated with reductions in AAMs in whole lung lysate and 
sections along with less ADORA2B-mediated pro-fibrotic cytokine IL-6 in BALF and 
fewer IL-6 positive macrophages. Antagonism and genetic deletion of ADORA2B 
followed by exposure to Th2 cytokines and hypoxia revealed a role for ADORA2B 
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itself in mediating macrophage differentiation into AAMs and the production of 
profibrotic mediators. These results supported a role for ADORA2B on myeloid cells 
in mediating their differentiation into AAMs and promoting production of profibrotic 
cytokines and chemokines that lead to the development and progression of pulmonary 
fibrosis.  
 Lung sections from patients with and without IPF along with bleomycin-induced 
lung fibrosis in Hif1::LUC reporter mice for the first time demonstrated stabilization 
of HIF1A in AAMs. Next, inhibition of HIF1A in late stages of a bleomycin-induced lung 
injury model revealed reductions in ADORA2B and AAM expression in association 
with attenuation of pulmonary fibrosis. Inhibition and genetic silencing of HIF1A in 
BMDMs also showed disruption of HIF1A-mediated ADOR2B expression, subsequent 
AAM marker expression including Arginase-1 and CD206. These results were 
confirmed in lung macrophages from mice after bleomycin treatment along with 
exhibiting reductions in IL-6 and CXCL1.  
 To further characterize the role of HIF1A in regulating ADORA2B expression 
subsequent development of fibrosis, a myeloid-specific HIF1A knockout mouse was 
exposed to saline and bleomycin. Results showed exacerbations in inflammatory 
parameters in acute stages of disease which lead to exacerbated lung fibrosis in late 
stages of disease as well. However, both ADORA2B and AAM expression remained 
reduced on day 33 after bleomycin exposure, confirming previous findings that HIF1A 
does regulate ADORA2B expression on AAMs. Further work to elucidate the 
mechanisms by which HIF1A deletion on myeloid cells contributes to breakdown of 
the alveolar-epithelial cell barrier and increased inflammation leading to the 
development of fibrosis is needed.   
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Figure 6.1. Working model of the hypoxic adenosine response on AAMs in lung 
disease. Patients with IPF have increased levels of adenosine and ADORA2B-
expressing AAMs (work done by Yang Zhou, PhD). (A) We demonstrate a role for 
ADORA2B on AAMs in contributing to the development of lung fibrosis due to (B) 
ADORA2B-mediated increases in macrophage differentiation into AAMs and 
subsequent pro-fibrotic mediator production. (C) Hypoxia-induced HIF1A stabilization 
in AAMs contributes to increased ADORA2B expression, (B) AAM differentiation, and 
development of pulmonary fibrosis which can be reversed with 17-DMAG treatment 
(a HIF1A inhibitor). (D) In acute lung injury, myeloid-specific HIF1A plays a tissue 
protective and (E) anti-inflammatory role. 
 
127 
 
This dissertation address several knowledge gaps with respect to how hypoxia 
alters adenosine signaling in lung disease and contributes to the development of 
fibrosis. We demonstrate a role for ADORA2B on myeloid cells in contributing to 
macrophage differentiation into AAMs, pro-fibrotic mediator production, and the 
development of lung fibrosis(113). I later illustrated how hypoxia through HIF1A acts 
as a major driver of ADORA2B on macrophages in BMDMs and for the first time, 
demonstrated its stabilization in human lung sections from patients affected by IPF in 
addition to murine models of bleomycin-induced lung injury. I then illustrated how 
inhibition of HIF1A in late stages of disease can attenuate lung fibrosis by reducing 
ADORA2B expression, AAM differentiation, and pro-fibrotic mediator production in 
vivo with supporting findings in BMDMs through genetic silencing and pharmacologic 
antagonism. Lastly, through myeloid-specific HIF1A deletion followed by bleomycin 
exposure, an anti-inflammatory role for HIF1A in myeloid cells is revealed in acute 
stages of disease.  
The findings from this dissertation are significant in that they emphasize the 
clinical importance of myeloid-specific ADORA2B antagonism or HIF1A inhibition in 
late stages of disease in attenuating the progression of lung fibrosis. These therapies 
could significantly prolong the lives of patients living with IPF by reducing symptoms 
or acute exacerbations, and ultimately, provide them a better quality of life. HIF1A 
stabilization in acute lung injury to reduce inflammation, breakdown of the pulmonary 
barrier, and worsened fibrosis in the long-term, also presents a novel therapy for 
patients affected by acute lung injury. Before translating to patient care however, the 
exact mechanisms behind HIF1A stabilization contributing to decreased inflammation 
need to be investigated further.  
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FUTURE DIRECTIONS 
 The work presented in this dissertation contributes to our understanding of how 
hypoxia modulates adenosine signaling and macrophage differentiation, contributing 
to pulmonary fibrosis. However, there are still many questions which remain to be 
answered and findings confirmed to delineate the mechanisms and key players in this 
complex disease process.  
 
What role does ADORA2B on myeloid cells contribute to pulmonary fibrosis 
development in comparison to other cell-types in the lung?  
 Deletion of ADORA2B on myeloid cells followed by bleomycin exposure 
showed attenuation of fibrosis but not complete abolishment of lung fibrosis. This 
suggests that myeloid-specific deletion alone is not enough to halt the progression of 
fibrosis and that the presence of ADORA2B on other cell-types may play a role 
including type 1 or 2 alveolar epithelial cells. To investigate this, ADORA2Bf/f mice 
crossed with mice carrying Cre recombinase under differing tissue-specific promoters, 
such as surfactant protein c (SPC) for type 2 epithelial cell-specific deletion or  
aquaporin 5 (Aqp5) for type 1 epithelial cell-specific deletion, should be exposed to 
bleomycin- induced lung fibrosis to delineate the role ADORA2B may play on these 
cell types in contributing to the development and progression of fibrosis(138).  
Differing roles for adenosine receptors on myeloid cells  
 Bone marrow derived macrophages exposed to Th2 cytokine treatment 
followed by hypoxia exposure and co-treatment with either pan-adenosine receptor 
agonist and ADORA2A or ADORA2B antagonism showed reductions in AAM 
129 
 
expression and profibrotic mediator production. Similar reductions were observed 
after hypoxia and Th2 cytokine treatment in mice with ADORA2A and ADORA2B 
global deletion as compared to wild-type control mice. Although, reductions in AAM 
and IL6 expression were more significant with ADORA2B antagonism or deletion, 
reductions secondary to ADORA2A antagonism or deletion are also evident. These 
observations are not surprising however given the work by Csoka et al. showing a role 
for ADORA2B and to  a lesser extent ADORA2A in mediating differentiation of 
macrophages after IL4 and IL13 treatment to the AAM subtype(108). As such, it would 
be interesting to evaluate how a mouse lacking both ADORA2A and ADORA2B on 
myeloid cells would respond to bleomycin treatment.  
 
Contribution of recruited versus resident macrophages 
  The robust response of ADORA3 to combined Th2 cytokine and hypoxia 
treatment do reveal limitations of the in vitro bone marrow derived macrophage 
system. ADORA3 is known to be elevated in bone marrow and peripheral 
mononuclear cells and are more representative of the circulating monocytes which 
travel through the vasculature and migrate to sites of injury or tissue of interest where 
they mature (139{Lech, 2013 #218, 140). Resident macrophages are believed to be 
the key players involved in acute inflammation in the lung even differentiating to the 
AAM subtype to promote repair in addition to Arginase-1 positive recruited 
macrophages(140). This observation elicits the question of what if any differences 
exist in adenosine receptor expression between recruited macrophages, such as 
those derived from bone marrow monocytes, and resident lung macrophages. Future 
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work investigating the contribution of ADORA2B or HIF1A specific deletion in resident 
(CD11c+) or recruited (CD11b+) macrophages in a bleomycin-induced model of lung 
injury will be useful to distinguish the differences in HIF1A-mediated changes in 
adenosine receptor expression, macrophage differentiation, and subsequent effects 
on acute or chronic lung disease(141, 142). Flow cytometry can be utilized to identify 
lung macrophage as alveolar (CD45+CD68hiF4/80+CD11b-CD11c+Gr1-), interstitial 
(CD45+CD68lowF4/80+CD11b+CD11c+Gr1-CD14low), monocytes 
(CD45+CD68lowF4/80+CD11b+CD11c-Gr1lowCD14hi), or dendritic cells 
(CD45+CD68hiF4/80-CD11c+Gr1-CD103+major histocompatibility complex (MHC) 
class IIhi) (143). Chao et al suggest that it is the alveolar macrophages when activated 
by hypoxia that contribute to mast cell degranulation and subsequent inflammation 
(144). Additionally, adenosine receptor expression may also differ between BALF 
macrophages of patients with and without IPF in comparison to murine lung or BAL 
macrophages after bleomycin exposure.  
 
Does HIF1A stabilization in other cell-types in contributing to the development 
of lung fibrosis?  
 Although we demonstrated that HIF1A is stabilized in AAMs in patients with 
and without IPF patients along with bleomycin-induced models of lung injury, these 
findings should be validated in BALF macrophages from human IPF patients samples 
as well. Examination of HIF1A stabilization in bleomycin exposed Hif1::LUC reporter 
mice along with work by Weng et al. suggest HIF1A activation in other key cell types, 
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such as type 2 alveolar epithelial cells, can contribute to epithelial cell proliferation and 
the development and progression of fibrosis(84). 
 
Effect of HIF1A inhibition, systemic versus localized, or myeloid-specific 
deletion on the development of pulmonary hypertension 
 In this dissertation, HIF1A was inhibited systemically through intraperitoneal 
delivery of 17-DMAG in late stages of bleomycin-induced lung injury. Evaluation of 
HIF1A levels in whole lung lysate showed that systemic 17-DMAG delivery was still 
able to achieve significant HIF1A knockdown which was associated with reductions in 
ADORA2B, AAM expression, and reduced lung fibrosis. Further experiments however 
should utilize targeted delivery to the lung through intranasal or intra-tracheal delivery 
of antisense oligonucleotides against HIF1A in order to minimize adverse effects of 
systemic 17-DMAG delivery, including fatigue, anorexia, renal dysfunction, and 
peripheral neuropathy(145). Localized or targeted delivery is also more desirable for 
translating therapies into novel treatments for patients.  
 Pulmonary hypertension is a known co-morbidity of patients with IPF. We 
demonstrated that myeloid-specific ADORA2B deletion followed by bleomycin 
exposure will result in improved pulmonary function parameters in comparison to 
control mice possessing ADORA2B on myeloid cells. Investigating the impact of 
myeloid-specific HIF1A deletion and inhibition of HIF1A in late stages of disease on 
the development of pulmonary hypertension will be insightful and could be potentially 
used in conjunction with existing therapies to treat PH associated with lung disease 
and idiopathic PH.  
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Possible contribution of HIF2A in myeloid cells to ADORA2B expression, 
macrophage differentiation, and fibrosis development 
HIF2A has recently been shown to contribute to the development of pulmonary 
hypertension and fibrosis in mouse models as well. Hickey et al. illustrated that 
homozygous mutation of VHL, contributes to the development of pulmonary edema, 
vascular remodeling, pulmonary hypertension, macrophage infiltration, and fibrosis 
which was reduced with the introduction of HIF2A heterozygosity(121). Hypoxia-
induced HIF2A stimulation has also been found to drive miR-120 expression in 
fibroblasts, repressing the c-myc inhibitor, MNT, driving the proliferation of IPF 
fibroblasts(146). Similarly, hypoxia-dependent HIF2A stabilization was recently shown 
to increase Arginase-1 expression inhibiting vasodilatory effects of its competing nitric 
oxide, leading to the development of pulmonary hypertension(129). To date, HIF2A 
expression has been believed to be limited to vascular endothelium and type 2 
alveolar epithelial cells(72). Preliminary work with genetic silencing of HIF2A by siRNA 
in BMDMs after Th2 cytokine treatment and hypoxia exposure suggest that HIF2A 
knockdown can be used as a means to reduce ADORA2B and AAM expression 
(Figure 6.2). Given these recent findings, future work will include evaluating the effects 
of inhibiting both HIF1A and HIF2A in myeloid cells in addition to myeloid-specific 
HIF2A deletion alone after bleomycin exposure on the development of fibrosis.  
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Figure 6.2. Genetic silencing of HIF1A and HIF2A alter macrophage 
differentiation and ADORA2B expression. Bone marrow derived macrophages 
from C57Bl6 mice were treated with 10ng/mL IL-4 and 10ng/mL IL-13 for 72 hours 
and then incubated in 2% O2 hypoxia for 12 hours in the presence of control siRNA, 
siRNA against HIF1A, and siRNA against HIF2A. (A) Immunoblot for HIF1A, AAM 
marker, CD206, ADORA2B, and -actin and (B) Arginase-1 expression, assessed 
using real-time PCR. Data presented as %-actin.  
 
Effect of Hypoxia-dependent versus hypoxia-independent pathways on 
ADORA2B and the development of pulmonary fibrosis 
HIF1A has also been shown to be stabilized in the absence of hypoxia through 
metabolites such as succinate, mechanical stretch, NF-kb activation (73-77). There is 
also evidence that ADORA2A and ADORA2B can mediate changes in glycolytic flux 
in association with the observation that CAMs and AAMs also utilize differing 
metabolic pathways(48, 74). Future work will include delineating the impact of 
ADORA2B in myeloid cells on macrophage metabolism, HIF1A stabilization, and 
macrophage differentiation. Understanding these pathways and changing 
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metabolomics of macrophages in the setting of hypoxia-induced and normoxia-
induced HIF1A stabilization in a bleomycin-induced model of lung injury can potentially 
be used as novel targets to stabilize HIF1A in acute lung injury or to inhibit HIF1A in 
chronic lung disease.  
 
Understanding the mechanisms behind which HIF1A stabilization in myeloid 
cells reduces acute lung injury 
We discussed in Chapter 5 the need to discriminate the mechanism by which 
HIF1A deletion on myeloid cells exacerbates acute lung injury. This includes 
assessing adenosine levels in BALF and evaluating CD73 or expression of other pro-
fibrotic or pro-inflammatory cytokines including TGF expression in whole lung lysate 
and lung sections. It is possible that HIF1A deletion contributes to CD73 down-
regulation, thus reducing the production of adenosine in the extracellular space and 
reducing adenosine-ADORA2B mediated protective effects in acute stages of 
disease.  
 
Interplay of HIF1A stabilization, endoplasmic reticulum (ER) stress, and 
macrophage differentiation, and lung injury 
Pereira et al. have demonstrated that combined insults of ER stress through 
activation of the unfolded protein response (UPR) and HIF1A stabilization can lead to 
significant elevations in hypoxia-response genes, including VEGF expression 
contributing to pulmonary angiogenesis and pulmonary hypertension development 
(147). Additionally, GRP78 is a chaperone protein which in the setting of ER stress, 
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recognizes exposed misfolded proteins and activates the UPR. Continued UPR 
activation in the setting of ER stress leads to up-regulation of C/EBP homologous 
protein (CHOP). Grp+/- mice showed protection from bleomycin-induced lung fibrosis 
in association with fewer lung macrophages that were indeed TUNEL, CHOP, and 
cleaved caspase-3 positive. CHOP-/- mice after bleomycin treatment however showed 
increase in fibrosis and arginase-1 positive lung macrophages (148).  
In support of a role for ER stress in AAMs in IPF, lung sections from patients 
with IPF and BLM model of lung fibrosis shows increase in CHOP+CD206+ 
macrophages and other ER stress markers. CHOP-/- protects against bleomycin-
induced lung injury in association with reductions in fewer Arginase-1 positive 
macrophages and reductions in TGF (149). STAT-mediated macrophage activation 
is through suppressor of cytokine signaling (SOCS) proteins of which IL-4 up-
regulates SOCS1, inhibiting STAT1, while IFN up-regulates SOCS3, inhibiting 
STAT3(96). The authors conclude that CHOP deficiency up-regulates SOCS1 and 
SOCS3 leading to down-regulation of STAT6/PPAR and subsequent disruption of 
AAM programing and infiltration into the lungs after bleomycin exposure, reducing 
fibrosis. Oh et al. have also demonstrated a role for ER stress in AAM differentiation 
in a mouse model of atherosclerosis (150).  
These recent studies suggest ER stress as a mechanism to HIF1A stabilization, 
AAM differentiation, and the development of pulmonary fibrosis or hypertension in 
mouse models of disease. Future work to evaluate the impact of ER stress on 
adenosine signaling and HIF1A-mediated ADORA2B expression, macrophage 
differentiation, and pro-fibrotic mediator production will be insightful and potentially 
lead to the identification of novel targets for drug development.  
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Evaluate role of hyaluronan production by myeloid cells in acute lung injury 
 We have previously demonstrated that myeloid-specific ADORA2B mediated 
deletion in mice followed by bleomycin exposure is associated with reduced 
hyaluronan production from macrophages in association with reductions in pulmonary 
fibrosis and hypertension (113). ADORA2B antagonism has also been shown to 
attenuate pulmonary hypertension in a mouse model of COPD in association with 
decreases in hyaluronan and enzymes involved in its synthesis including hyaluronan 
synthase 2 (HAS2)(151). Interestingly, high molecular weight (HMW) hyaluronan 
production by epithelial cells has been found to have a protective effect in ALI (41). 
The role of HIF1A and adenosine signaling in mediating this protective effect on 
epithelial cells in addition to characterizing hyaluronan production by myeloid cells in 
ALI should be investigated in future work to evaluate adenosine-mediated ECM 
production as a target for ALI or IPF.  
 
CONCLUSIONS 
We utilize an established mouse model of chronic lung injury, lung samples 
from patients with IPF, along with a robust in vitro system of bone marrow derived 
macrophages to elucidate the effects and interactions of adenosine signaling, 
macrophage differentiation, and hypoxia on pulmonary fibrosis. We have illustrated a 
role for ADORA2B in mediating macrophage differentiation into AAMs, promoting the 
production of pro-fibrotic cytokines in mouse models of lung injury and in vitro culture. 
For the first time, we demonstrate inhibition or genetic silencing of HIF1A can 
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attenuate pro-fibrotic mediator production and pulmonary fibrosis in bone marrow 
derived macrophages (BMDMs) and in vivo models of bleomycin-induced pulmonary 
fibrosis. Finally, we reveal a tissue-protective and anti-inflammatory role for HIF1A in 
acute stages of lung injury. Further investigations are needed to validate the 
mechanism by which deletion of HIF1A contributes to exacerbated inflammation and 
subsequent fibrosis in addition to validation in human IPF tissue and macrophage 
samples.  
There exists a great need to develop novel therapeutics to halt the development 
and progression of IPF. Through this work, we have found a role for HIF1A in 
mediating ADORA2B expression on macrophages, contributing to their differentiation 
into the reparative AAM subtype, and ultimately, contributing to the secretion of pro-
fibrotic mediators leading to the progression of lung fibrosis. Genetic deletion of 
ADORA2B on myeloid cells and inhibition of HIF1A late stages of disease has 
illustrated significant reductions in the development of fibrosis in bleomycin-induced 
models of lung injury suggesting their importance as therapeutic targets for drug 
development; additionally, myeloid-specific HIF1A stabilization may be another 
approach to reduce inflammation in acute lung injury. Much work remains to validate 
findings in human tissue samples before moving to clinical trials in patients to 
understand the safety, efficacy, and long-term effects of ADORA2B antagonism or 
HIF1A inhibition, and HIF1A stabilization, for treatment of IPF or ALI. Ultimately, these 
investigations will lead to a better understanding of the role of adenosine in IPF and 
ALI, leading to identification of targets for novel therapeutics that can prevent disease 
progression and possibly reverse lung fibrosis and inflammation. Additionally, the 
inflammatory cell response and fibrosis observed in IPF shares features of other 
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common diseases including asthma and systemic scleroderma which respectively 
affect up to 300 million and 2.5 million individuals worldwide(152-154). Treatments 
developed for IPF may overlap and offer potential benefit in these diseases as well. 
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